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Development of a New Independent Monte Carlo Dose Calculation Quality Assurance 
Audit Tool for Clinical Trials 
 
Austin Michael Faught 
Advisory Professor: David S. Followill, Ph.D. 
 
Introduction:  Commercially available treatment planning systems (TPS) may use a number of 
different radiation dose calculation algorithms during the planning process. The Radiological 
Physics Center (RPC), tasked with ensuring clinically comparable and consistent dose delivery 
amongst institutions participating in NCI funded multi-institutional clinical trials, has traditionally 
relied upon measurements to achieve this objective. As a supplement to the tools used by the 
RPC, an independent dose calculation tool is needed to determine patient dose distributions in 
three dimensions so as to act as a quality assurance tool for the dose calculations.  
 
Methods:  Multiple source models representing the output of Elekta 6MV and 10MV and 
Varian TrueBeam Flattening Filter Free (FFF) 6MV and FFF 10MV therapeutic x-ray beams 
were developed. The Monte Carlo technique, using the Dose Planning Method (DPM) 
algorithm, was used in radiation dose calculations. During validation calculations were 
compared to open field measurements in a water phantom. Benchmarking was a measurement 
based comparison of mock treatment plans in anthropomorphic phantoms. Treatment plans 
included intensity modulated radiation therapy and stereotactic body radiation therapy 
techniques. Past phantom treatment plans submitted through a remote auditing program were 
recalculated using the tool and compared to submitted measurement data as a test of the 
models’ robustness. 
 
Results: The average percentage of data passing a ±2%/2mm gamma criterion during 
validation testing was 99.5%, 99.6%, 98.1%, and 98.1% for Elekta 6MV, 10MV, Varian 
iv 
 
TrueBeam FFF 6MV, and FFF 10MV beams, respectively. The percentage of data passing the 
benchmarking evaluation criterion of ±3%/2mm was 87.4%, 89.9%, 90.1%, and 90.8% for 
Elekta 6MV, Elekta 10MV, Varian TrueBeam FFF 6MV, and Varian TrueBeam FFF 10MV 
beams, respectively.  
 
Conclusions: Elekta 6MV and 10MV and Varian TrueBeam FFF 6MV and FFF 10MV multiple 
source models based on dose calculations using the DPM Monte Carlo code were successfully 
developed, validated, and benchmarked against measurements. A recalculation of TPS dose 
from archived phantom credentialing audits was performed as a proof of concept for the 
models’ utility as a quality assurance tool for use in clinical trial audits. 
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Chapter 1: Introduction 
 
1.1 Statement of Problem 
          The Radiological Physics Center (RPC) is one of three National Cancer Institute (NCI) 
funded, quality assurance (QA) offices that provides QA auditing services to institutions 
participating in NCI cooperative clinical trials. The RPC has developed several programs as a 
means to efficiently provide dosimetric and QA services to the clinical trial community and to 
ensure NCI that the institutions participating in clinical trials deliver comparable and consistent 
radiation doses. The RPC’s QA programs are comprised of on-site evaluations and remote 
auditing tools. The on-site evaluations consist of interviews of personnel that perform physical 
measurements on the therapy machines, a review of quality control procedures, measurement 
of basic beam dosimetry data, and a review of patient dose calculations. The remote auditing 
tools are used to review patient dose calculations, measure reference beam output with 
optically stimulated luminescence dosimeters (OSLD), and evaluate advanced treatment 
procedures with anthropomorphic QA phantoms.  The anthropomorphic QA phantoms are 
designed to test the entire treatment process beginning with imaging of the patient and 
continuing through treatment planning, set-up, and delivery of the prescription dose. This is 
done by comparing measurements from the phantom’s thermoluminescent dosimeters (TLD) 
and radiochromic film to predicted values obtained from the institutions’ calculations performed 
by the treatment planning system[1]. 
     Measurement based comparisons historically have provided acceptable assurance 
evaluating an institution’s ability to accurately deliver dose for conventional treatment 
procedures. With recent advances in radiotherapy that allow for highly conformal dose 
distributions and steep dose gradients  through the use of multi-leaf collimators (MLC), dynamic 
wedges, and advanced delivery techniques including three dimensional stereotactic 
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radiosurgery and intensity modulated radiation therapy (IMRT), there is a growing concern that 
the limits of measurement uncertainty are being approached[2]. As reported by the New York 
Times, increased complexity in treatment modality creates the potential for devastating errors 
in the administration of therapeutic radiation [3-10].   In addition, patient dose calculations in the 
lung or near bony anatomy using the new treatment delivery technologies require the use of 
heterogeneity correction dose algorithms that the RPC is currently not able to fully verify with its 
current QA tools. The RPC has published results detailing the associated uncertainty with 
TLD[11] and radiochromic film[12] as well as the results from the remote anthropomorphic 
phantom audit program that present the ability of institutions to conform to prescribed treatment 
plans[13-17]. These publications show a varying degree of compliance among the treatment 
plans with variability among different plans generated from the same treatment planning 
system (TPS). There is reason to believe that these plan variations could be from the beam 
commissioning process, delivery of the treatment, and the accuracy of the dose calculation 
algorithms used by the TPS[12, 18, 19]. The observed differences between institutions have 
caused concern that variations and inaccuracies in the delivery of radiation therapy between 
institutions could negatively impact patient safety and compromise the conclusions drawn from 
NCI supported multi-institutional clinical trials. Currently the RPC has no means by which to 
check the dose calculations made by the TPS for IMRT and heterogeneity corrected treatments 
to catch any errors resulting from the dose calculation algorithms. In order to evaluate the 
actual dosimetry and judge the accuracy of the TPS predicted dose distributions, a trusted 
independent dose calculation tool is needed. This would also allow for retrospective analysis of 
past clinical trials in which all dosimetry data could be normalized based on an independent 
dose calculation standard. 
     For this reason, the RPC began the development of a multiple source model that is  
executed using the Monte Carlo (MC) technique for dose calculations[20, 21]. The MC 
technique is a means to numerically solve the transport equation by means of simulating the 
stochastic processes using random sampling.  It has been generally accepted as the most 
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accurate means of radiation dose calculation[22] and is particularly useful in calculations in 
which interfaces between materials along the transport path exhibit large differences in density 
and/or atomic numbers[23]. The accuracy of the MC technique has been tested against 
deterministic algorithms for a variety of codes including EGS4[24, 25], ITS[26, 27], MCNP[28], 
and PENELOPE[29-31]. Despite its superior accuracy compared to deterministic methods, MC 
based methods have not been widely implemented into the radiotherapy clinic due to the 
computational intensity of the calculations[22, 23]. Recent improvements in MC code and 
improvements in technology that have resulted in increased computational speed have 
motivated increased consideration to treatment planning systems utilizing MC techniques[22, 
32]. 
     The improved accuracy of the MC technique is of particular significance in calculating dose 
in tumors that lie near lung/air interfaces in the body [22, 33]. In these regions, tissues and air 
cavities may have radiological properties that are substantially different from water. This 
necessitates heterogeneity corrections for standard deterministic methods of calculating 
dose[34]. Davidson et al. have documented how these correction factors may lead to 
differences between measurement and calculation in heterogeneous media when using 
conventional analytical dose calculation algorithms[12, 18].       
     The RPC’s previously developed multiple source model[35], a dose calculation tool for 
Varian (Varian Medical Systems, Palo Alto, California) 6MV and 10MV photon beams, was 
executed using the Dose Planning Method (DPM) code. The open source code allows for easy 
modification and interfacing, making it a good choice of code to execute the MC simulations. 
DPM uses standard condensed history modeling for electron transport, and is what’s known as 
a mixed scheme[23]. This means that large energy transfer collisions are treated in an 
analogue sense (event-by-event) and small loss collisions are approximated using the 
continuous slowing down approximation (CSDA) using a restricted stopping power[22, 23]. 
Photon transport is handled on an interaction by interaction basis and is composed of 
photoelectric absorption, Compton scattering, and pair production[23]. By altering the transport 
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mechanics such that large electron transport steps may be taken, even across heterogeneous 
boundaries while maintaining the necessary accuracy, the computation speed has been greatly 
improved, keeping differences between DPM and other MC codes below 1.25% and statistical 
uncertainty on the order of 0.2% of the maximum dose[23].  
     To aid in integrating the source model with the DPM code, a graphical user interface 
designed to run off the Computational Environment for Radiotherapy Research (CERR)[36] 
software platform was designed in the application MATLAB (MathWorks Inc., Natick, MA). 
CERR was developed to create a common data structure for treatment plan databases that 
would facilitate multi-institutional collaborations amongst the radiation therapy community.  
     Within radiotherapy treatment planning and dose calculation, the linear accelerator output 
may be modeled in three primary ways. First, a complete simulation of the linear accelerator 
mechanics may be done and saved to a phase space plane for further simulations in the future. 
While more rigorous, this method is strongly influenced by hardware specifics that may be 
difficult to ascertain or are proprietary in nature. It also requires the most memory usage of the 
three methods [37-40]. Second, an analytical description of the output, based on the full 
simulation, may be used in the form of a multiple source model. The multiple sources arise 
from the grouping of photons based on their last interaction prior to being stored in the phase 
space plane [37-44]. The final means, and method of choice for the RPC’s model, is a 
measurement based multiple source model in which output is matched to standard dosimetry 
data. This has the advantage of being independent of the complexities within the treatment 
head[22]. Parameters to the analytical models describing the multiple sources are derived by 
minimizing the difference between simulated and measured data [45-49].  
     Currently, the multiple source model is comprised of three analytical components describing 
the output of a therapeutic megavoltage photon beam. The components correspond to the 
primary source in the treatment head, an extra-focal scattering source, and a source to model 
electron contamination in the beam. The analytical model is coupled to the DPM code where 
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simulation of the particle transport occurs resulting in the independent dose calculation tool[20, 
21].  
     The primary point source represents isotropically emitted photons originating from the target 
inside the linac head. A second, extra-focal source is added to model scattered photons within 
the linac head and is placed at a location corresponding to the flattening filter within the linac. 
While only included in the Varian 10MV model done by Davidson et al., a third source 
representing electron contamination may sometimes be added to the model. Studies have 
suggested that this source may not be necessary for linacs of nominal energies less than or 
equal to 10MV.  
     This project will be based on the extension of the currently developed multiple source model 
for Varian megavoltage, therapeutic, linear accelerators to include linear accelerators 
manufactured by Elekta (Elekta AB, Stockholm, Sweden) and Flattening Filter Free Varian 
TrueBeam with nominal beam energies of 6MV and 10MV. In its current stage, the calculation 
tool may be used as a generic model for Varian linacs of different models. By extending the tool 
to Elekta and Flattening Filter Free Varian TrueBeam, the RPC will be able to use the tool for 
most of the remaining 25% of machines used clinically. While specific models of a 
manufacturer have been extensively modeled using the Monte Carlo technique[39, 50, 51], 
there have been a limited number of studies exploring generic models meant to cover a range 
of models by a manufacturer[52-54]. RPC measured dosimetry data suggests that a standard 
dataset can match measurements from modern linear accelerators of the same nominal energy 
and manufacturer[55, 56]. 
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1.2 Benefits to Science 
     The RPC wishes to incorporate the generic model into a fully integrated calculation tool for 
use in analysis of clinical trial data. This tool would allow for the accurate modeling of nearly all 
megavoltage, therapeutic photon beams monitored by the RPC[55, 56] and easy importation of 
treatment plan data including beam and MLC configurations and CT data representing the 
calculation grid for dose calculations. This tool will have four primary uses within the RPC’s QA 
program: 
1) It will complement the anthropomorphic phantom program by allowing for an 
additional data source in comparison of measurement data and TPS calculated 
dose distributions. 
2) It may act as means to provide direct comparison of retrospective patient treatment 
plans from clinical trials. This would isolate the performance of the TPS dose 
calculation from all other variables in the treatment process. 
3) It will allow for the comparison of TPS dose calculation algorithm performance. RPC 
studies[13-17] have shown that discrepancies between TPS data and measured 
data from the phantom QA program can be largely dependent on beam modeling 
errors, planning mistakes, and errors in phantom set up. By importing a single 
treatment plan to the institution TPS for dose calculation, the performance of the 
TPS calculation may be objectively compared through the use of a standard 
baseline established by the calculation tool using the DPM engine.  
4) Extension of the calculation tool to include a flexible source model for Elekta and 
Flattening Filter Free Varian TrueBeam machines will act as a valuable quality 
assurance tool that allows the RPC’s quality assurance program to test areas of the 
radiation therapy treatment process previously not possible. 
      
     The new models will be developed and commissioned in a step by step process beginning 
with validation against basic dosimetry data, benchmarking against phantom based 
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measurements, and finally benchmarking against outside institution phantom measurements 
previously submitted through the RPC’s credentialing program. A detailed explanation of the 
proposed methods and issues to be resolved are contained below. 
 
1.3 Hypothesis and Specific Aims 
 
Hypothesis: A dose calculation quality assurance tool using the Dose Planning Method Monte 
Carlo technique coupled to multiple source models of Elekta 6MV and 10MV and Varian 
TrueBeam FFF 6MV and FFF 10MV beams can perform dose calculations to an accuracy of 
±3% of the maximum dose and ±2mm distance to agreement for conformal radiation therapy 
and intensity modulated radiation therapy in homogeneous and heterogeneous media as 
determined by anthropomorphic phantom based measurements. 
 
Specific Aim 1: Modify and extend a multiple source model dose calculation tool previously 
developed for Varian linear accelerator (linac) 6MV and 10MV photon beams to include Elekta 
6 MV and 10MV, and Varian TrueBeam FFF 6MV and FFF 10MV photon beams using the 
same model optimization process. The dose calculation tool will be validated, and the accuracy 
will be verified against depth dose data and dose profiles for field sizes up to 40 x 40 cm2. 
Acceptance between the dose calculation and measured dosimetry data is ±2%/2mm distance 
to agreement (DTA) for 90% of all data. 
 
Specific Aim 2: The dose calculation tool will be benchmarked against measurements for 
Elekta 6MV and 10MV and Flattening Filter Free Varian TrueBeam 6MV and 10MV photon 
beams using the Radiological Physics Center’s (RPC) anthropomorphic phantoms. These 
phantom measurements will include measurements for a homogeneous intensity modulated 
radiation therapy (IMRT) head and neck phantom, stereotactic lung phantom, and 
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heterogeneous IMRT lung treatments. The accuracy of the dose calculation tool will be within 
±3%/2mm DTA of measurements for 85% of the data tested. 
 
Specific Aim 3: The dose calculation tool will be benchmarked against measurements 
submitted by outside institutions as a part of the Radiological Physics Center’s remote auditing 
program. Plans will be selected to include previously passing deliveries that will test the 
robustness of the models and their ability to predict dose distributions from linear accelerators 
whose dosimetry data were not used during commissioning and validation of the models. 
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Chapter 2: Materials and Methods: Development, Validation, and Benchmarking 
2.1 Introduction 
     Interest in the Monte Carlo (MC) technique as means for dose calculations has been 
motivated by its superior accuracy compared to traditional, deterministic algorithms[22]. While 
different codes utilizing the technique have been developed[23, 25, 28-30], all operate under a 
similar idea that with known interaction probability distributions of electrons and photon 
radiation may be transported with a high degree of statistical certainty. While deterministic 
algorithms used by modern day treatment planning systems have been shown to perform well 
in dose calculations, there have been demonstrated instances of disagreement between 
calculated and measured data in conditions of heterogeneous media, small field sizes, and/or 
steep dose gradients[12, 18]. Due to challenges associated with measuring a full three-
dimensional dose distribution in realistic clinical circumstances (e.g. within an anthropomorphic 
phantom), the MC technique is an excellent way to evaluate the performance of commercial 
treatment planning dose calculation algorithms. 
     Traditionally MC dose calculations are performed via a full simulation of the mechanics 
within the linear accelerator. Depending on the dosimetric quantities of interest and the 
measurement conditions, results may be highly dependent on the accuracy and completeness 
of the model geometry. Out of field doses in particular rely upon more than the general beam 
line components such as target, flattening filter, jaws, and multi-leaf collimator (MLC) that can 
model standard in field dosimetric quantities. The execution of this type of model can be 
cumbersome as the level of detail needed in modeling specific components may be considered 
proprietary information by the manufacturer and as a result not readily available. Alternate 
means of modeling as detailed in the American Association of Physicists in Medicine’s Task 
Group Report No. 105 (TG-105)[22] have been implemented. These include a multiple source 
model based on the full simulation of an accelerator in which particles are grouped based on 
their points of interaction and described analytically. A third method is a measurement based 
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multiple source model in which an analytical description of particles is generated based on 
minimizing differences between resultant calculated data and measured data. 
     Another obstacle to the wide spread implementation of MC dose calculations has been its 
computational intensity. Within a clinical environment, it is not always practical to wait for a 
dose calculation with sufficient statistical certainty. Advances in computer technology and the 
use of GPU based calculations have cut the required time down substantially and renewed 
interest in clinical MC calculations. Additionally alternate approaches of simplifying the MC 
transport have been developed to cut down on calculation time [23, 57, 58]. 
     Originally developed and commissioned for field sizes up to 10 x 10 cm2 by Joseph Deasy 
and his research group out of Washington University in St. Louis[20], the RPC has documented 
its modifications and development of an independent, dose calculation, quality assurance tool 
for Varian linear accelerators of nominal photon beam energies 6MV and 10MV up to field 
sizes of 40 x 40 cm2 including fields modulated by MLCs[21, 35]. This tool was designed with a 
generic model of Varian megavoltage, therapeutic, x-ray beams such that individual beam 
models would not be needed for every beam monitored by the RPC. In short, the model was a 
measurement-driven multiple source model consisting of analytical descriptions of a primary 
point source, an extra-focal disk source, and an electron contamination source. The model was 
shown to accurately account for off-axis effects, namely increased fluence and decreased 
mean energy, resulting from the flattening filter.  
     It’s estimated that the current dose calculation tool covers approximately 75% of the beams 
monitored by the RPC. Notable exclusions are Elekta and Siemens manufactured linear 
accelerators and linear accelerators operating in flattening-filter-free mode, notably the Varian 
TrueBeam accelerator. Chapter 3 reports on the development of Elekta 6MV and 10MV 
therapeutic x-ray beam models to be included in the dose calculation tool, and Chapter 4 
reports on the inclusion of a Varian TrueBeam linear accelerator operating in flattening filter 
free mode. Validation of the models was tested by comparing ion chamber measurements in a 
water phantom for depth dose data and dose profiles for square field sizes. Benchmarking was 
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performed using the RPC’s anthropomorphic phantoms that contain thermo-luminescent 
dosimeters (TLD) and radiochromic film. In this stage the entire model was evaluated in 
clinically realistic scenarios including both homogenous and heterogeneous media with highly 
modulated and small fields.  
 
2.2 Source Model 
2.2.1 Hardware 
     Dose calculations were performed on a Hewlett Packard ProLiant DL585 G5 3.2 GHz server 
with four AMD Opteron™ processors with four core CPU’s and 32 GB of RAM (Hewlett-
Packard Company, Palo Alto, CA) and a Hewlett Packard ProLiant DL380 G8 server with two 
Xeon® CPU E5-2602 with six core CPU’s (Hewlett-Packard Company, Palo Alto, CA). 
 
2.2.2 Software 
     Calculations and analysis were performed with MATLAB (MathWorks Inc., Natick, MA) and 
the use of the Computational Environment for Radiotherapy Research (CERR)[36]. Execution 
of the MC code was done using the Dose Planning Method (DPM)[23] utilizing low energy 
electron and photon cutoffs of 200 keV and 50 keV, respectively. To cut down on calculation 
time, each simulation was broken into smaller batches and individual beams such that 
calculations were allocated to individual processors using MATLAB’s Parallel Processing 
Toolbox.  
 
2.2.3 Source Model Commissioning 
     The commissioning of a source model was completed in two steps. The first was based on 
central axis depth dose data from a 10 x 10 cm2 field size. Separate dose calculations were 
performed for mono-energetic bins of 0.25 MeV increments through the nominal energy range 
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of the beam for both primary and extra-focal sources. The relative weight between each of the 
bins was adjusted during an optimization process to match measured percent depth dose data 
(PDD).  
     Optimization involved the adjustment of seven unique parameters used to describe the 
shape and position of the primary and extra-focal energy spectra, relative fluence of the 
primary and extra-focal sources, electron contamination contribution, and a parameter used to 
model the volume average blurring from the use of an ion chamber in collecting measurement 
data. The parameters used to describe the energy spectra shape were based on the product of 
a Fatigue-Life function and Fermi Distribution, shown below in Equation 2.1, and referred to as 
a Fatigue Fermi Distribution by Davidson et. al[20, 21, 35]. 
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)   (2.1) 
Such that E>µ; γ,β>0 
 
In the above equation, E is the photon energy, EF the cut-off energy, and µ, β, and γ shape the 
photon spectrum. This function was chosen for the Elekta model to 1) be consistent with the 
spectra modeling used for the Varian models by Davidson et al. [20, 21, 35] and 2) its ability to 
fit the photon spectra from numerous linac manufacturers determined from the Monte Carlo 
code BEAM and studied by Sheikh-Bagheri and Rogers[59] without being overly 
parameterized. 
     The distribution matched exactly with the Varian model with the exception that the locations 
of the extra-focal source and electron contamination source were moved to be consistent with 
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the location of the flattening filter within Elekta machines. Briefly, these distributions consisted 
of a primary point source corresponding to photons created within the target, an exponential 
disk source[60] used to model photons originating from scatter events in the linac head 
(primary collimator, jaws, MLC, flattening filter, etc.) and a uniformly distributed, circular 
electron contamination source. The energy distribution for the extra-focal source is modeled by 
the same distribution as the primary source, Equation 2.1, but scaled down in the relative 
fluence and maximum energy. The electron contamination source has an energy spectrum 
modeled by an exponential function described by Fippel et al. [53] for Elekta and Siemens 
linacs. Its relative contribution was determined during the optimization process and was 
included in both Elekta 6MV and 10MV and TrueBeam FFF 6MV and FFF 10MV models, 
contrary to the Varian model in which Davidson et al.[35] chose to exclude it for the 6MV 
model. 
     The output of the MC simulation is in units of energy per source particle. To convert the 
resultant calculations into the more useful units of dose per monitor unit (MU), the output was 
scaled by a constant factor to match the dose at a depth of dmax for the 10 x 10 cm
2 
measurements and calculations. 
     The second step of the commissioning process is based on measured data from a 40 x 40 
cm2 field size, and is executed with the intention of modeling off-axis effects such as increased 
off-axis fluence and decreased mean energy off-axis, collectively contributing to the Horn 
Effect. Using the optimized spectra from the first step and an off-axis correction for half-value 
layer (HVL) formulated by Tailor et al. [61] (Elekta models) and Georg et al.[62] (TrueBeam 
FFF Models) and implemented without change, calculations were run for 1600 1 x 1cm2 
beamlets, making up an open 40 x 40 cm2 field. Each beamlet’s contribution to the total dose 
was adjusted based on a piecewise linear function such that the calculated dose profiles were 
matched to measured dose profiles at a depth of dmax.  
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2.2.4 Machine Output Correction 
     Similar to the output correction used by Davidson et al.[35], and documented in the 
literature[63, 64], a second order hyperbolic equation was used to correct for machine output 
as a function of field size for the Elekta models. This was done by a least squares fit of the ratio 
of calculated and measured output factors as a function of field size. The correction factor was 
then applied to the entire three-dimensional (3D) dose matrix after calculation. No output 
correction was needed for the Varian TrueBeam FFF models. 
 
2.2.5 Fluence Map 
     A projected fluence map at isocenter was formed with dimensions determined by the jaw 
settings. This map was divided into 1 x 1 mm2 fluence segments with the option of a finer 0.5 x 
0.5 mm2 at the cost of increased computation time and memory. The fluence through each 
fluence segment was determined from MLC position pulled from the DICOM plan file for each 
plan segment, the transmission through the MLC leaves, transmission through the rounded leaf 
ends, and the leakage between adjacent leaves. Each group of fluence segments exposed to 
the primary source during the plan segment were assigned a fluence based on the number of 
monitor units per plan segment. The transmission through the MLC assigned additional fluence 
to the fluence segments as a percentage of the monitor units in an amount that varied along 
the leaf length with the least amount being at the rounded tips of the leaves. A piecewise linear 
function was used to weight the fluence in this region to model the rounded tip. The fluence 
segments that this function was applied to corresponded to the projected width of the leaves at 
isocenter and an effective tip length of 5mm. This resulted in a more effective modeling of the 
penumbra caused by the shape of the leaves. Interleaf leakage was modeled by assigning 
additional fluence, expressed as a percentage of the monitor units, to the fluence segments. 
This was done along the fluence segments alongside the leaves in 1mm wide region with 
length corresponding to the leaf positions. A final, composite fluence map was calculated by 
summing the 1 x 1 mm2 fluence segments from all beam segments determined in the treatment 
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plan. The DPM calculation was then run by segmenting the fluence map into beamlets of 
similar monitor units.   
 
2.2.6 Primary Source Size 
     The primary source corresponding to photons created within the target of the linear 
accelerator head was treated as a point. In reality, it is known that this is finite in size and 
ranges, dependent on linear accelerator manufacturer, from 0.5mm to 3.4mm in full width at 
half the maximum[65]. The finite size of the source results in an exaggerated penumbra, 
dependent on source size, distance from the collimator jaws, and distance between the 
collimator jaws and point of measurement, referred to as the geometric penumbra. To mimic 
this effect in a point source model, an offset in the MLC leaf positions was implemented in the 
amount of 0.4mm. This remains unchanged from the previously developed Varian model[20, 
21, 35].  
 
2.2.7 Electron Contamination Contribution Versus Field Size 
     Similar to the overall output correction discussed in 2.2.1.4, a field size dependent output 
correction was used for the electron contamination contribution in the Elekta models. This too 
was a second order hyperbolic equation. This correction was necessary to model the increased 
head scatter contribution with relation to the field size which affects the build-up region of the 
depth dose curves and the depth of maximum dose. No field size dependent correction factor 
was used for the Varian TrueBeam FFF models. 
 
2.3 Validation Testing 
     Validation of the Elekta source models was done through a comparison of calculated 
dosimetry values to basic, measured beam data. Specifically that data consisted of depth dose 
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curves and dose profiles at depths of 1.6cm (dmax), 5.0cm, 10.0cm, and 20.0cm for the 6MV 
model and 2.0cm (dmax), 5.0cm, 10.0cm, 20.0cm, and 25.0cm for the 10MV model.  These 
comparisons were done for field sizes of 3 x 3 cm2, 5 x 5 cm2, 10 x 10 cm2, 15 x 15 cm2, 20 x 
20 cm2, and 30 x 30 cm2. Measurements were performed in a water phantom and calculations 
were done in a simulated 50 x 50 x 50 cm3 water phantom. 
     Validation of the Varian TrueBeam FFF 6MV and FFF 10MV models was done through a 
comparison of calculated dosimetry values to basic, measured beam data. Data consisted of 
depth dose curves and dose profiles at depths of 1.5cm (dmax), 5.0cm, 10.0cm, 20.0cm and 
30.0cm for the FFF 6MV model and 2.4cm (dmax), 5.0cm, 10.0cm, 20.0cm, and 30.0cm for the 
FFF 10MV model. These comparisons were done for field sizes of 3 x 3 cm2, 4 x 4 cm2, 6 x 6 
cm2, 8 x 8 cm2, 10 x 10 cm2, 20 x 20 cm2, 30 x 30 cm2, and 40 x 40 cm2. Measurements were 
performed in a water phantom and calculations were done in a simulated 50 x 50 x 50 cm3 
water phantom. 
     The calculated data was extracted from the 3D dose matrix relative to the surface of the 
virtual water phantom, as defined by the skin contour. The resolution of the calculated data was 
0.2cm in the depth direction, defined as ‘y’ in the CT data set, 0.2cm in the in-plane direction, 
defined as ‘x’ in the CT data set, and 0.3cm in the cross-plane direction, defined as ‘z’ in the CT 
data set.  
     The measured data was the same data used for the commissioning of the clinical treatment 
planning system and were performed using a Wellhöfer CC13 ionization chamber (internal 
volume of 0.13cc) manufactured by CNMC (Best Medical, Nashville TN) for the Elekta 
measurements and a PTW 31010 ionization chamber (internal volume of .125cc) (PTW, 
Freiburg, Germany) for the Varian TrueBeam FFF measurements. To account for volume 
averaging effects of the ionization chamber that exaggerate the penumbra, a Gaussian 
convolution was applied to all dose profiles for comparison of measured and calculated data. 
The standard deviation of the kernel applied in the convolution was one of the seven 
parameters defined during model optimization. 
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     Agreement between measured and calculated data was evaluated using gamma analysis 
with a criterion of ±2% of the maximum dose and ±2mm distance to agreement. For dose 
profile comparison, the analysis was performed out to an off-axis distance corresponding to 5% 
of the maximum central axis dose.  
2.4 Anthropomorphic Phantoms 
     The RPC’s anthropomorphic head and neck phantom, shown in Figure 2.1, consists of a 
hollow, plastic head that may be filled with water to mimic radiological properties similar to 
tissue. Contained within the hollow shell is a removable insert constructed of polystyrene with 
solid water structures representing two separate targets and a single organ at risk (OAR). Also 
contained in the insert is space for the placement of radiochromic film (Gafchromic EBT2, 
Ashland Inc., Covington, KY) in the axial and sagittal directions and thermoluminescent 
dosimeter (TLD) capsules (TLD-100 capsules, Radiation Detection Company, Gilroy, CA). The 
orientation of the insert within the shell, and the targets and OAR within the insert, are such that 
the phantom presents a clinically realistic challenge. For detailed specifications about the 
phantom design, the reader is referred to an article published by Molineu et al.[66]. 
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Figure 2.1: The anthropomorphic, hollow, plastic shell to the RPC’s head and neck phantom 
with the polystyrene insert removed and opened. The polystyrene insert in the RPC’s head and 
neck phantom is opened up to reveal a transverse, cross sectional view. The insert contains a 
primary PTV, secondary PTV, and critical structure made of solid water that may be 
distinguished from the insert in a CT scan for treatment planning purposes. Also pictured are 
the holes to house the thermoluminescent dosimeters (TLD) for absolute dosimetry. The 
orthogonal slits intersecting in the primary PTV are for sagittal an coronal films while an axial 
film may be placed between the two halves to the insert shown in this cross sectional image. 
 
     The planning criteria established by the RPC and RTOG protocol H-002 for credentialed 
institutions will be used in the benchmarking study. It is as follows: 
1) 6.6 Gy delivered to 95% of the primary PTV 
2) 5.4 Gy delivered to 95% of the secondary PTV 
3) Less than 1% of the PTVs may receive less than 93% of the prescription dose 
4) OAR is to receive a dose less than 4.5 Gy 
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5) Normal tissue dose must be held under 110% of the prescription dose 
  
     The heterogeneous, anthropomorphic thorax phantom designed by the RPC, shown in 
Figure 2.2, consists of a hollow PVC shell filled by water that contains structures of varying 
materials representative of human anatomy including a heart (nylon), spine (PBT-polyester), 
lungs (compressed cork), and a lung tumor (polystyrene). To simulate the slope of a human 
chest, the anterior surface of the outer shell is slightly angled. At a position consistent with the 
left lung, the phantom contains a removable imaging/dosimetry insert. Within the dosimetry 
insert is space for TLD capsules and radiochromic film in the axial, sagittal, and coronal planes. 
A detailed description of the phantom specifications can be found in the literature[67].  
 
 
Figure 2.2: The outer shell of the RPC’s thorax phantom with the lung insert partially removed. 
Within the insert are slits for the placement of radiochromic film and holes for TLD. Rods 
containing TLD capsules are also inserted into the shell for point dose measurements 
corresponding to the location of the spinal cord and heart, the representative critical structures 
for this treatment. Also pictured (right) is the disassembled lung insert with locations for 
radiochromic film and TLD and the removed TLD rods (bottom left). 
 
TLD Rods 
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     Planning criteria decided upon by the RPC and RTOG protocol 0236 to be used in the 
benchmarking study are as follows: 
1) 66 Gy to 95% of the PTV (clinically delivered in 33 fractions) 
2) Less than 45 Gy to the spinal cord 
3) Less than 20 Gy to 40% of the lung 
4) Less than 40 Gy to the entire heart 
5) Less than 50 Gy to 50% of the heart 
 
     The dosimeters contained within the phantom are all specified at doses less than the clinical 
constraints given above. Therefore all plans will be scaled down by a constant factor of 11 and 
delivered in a single fraction[35, 67]. 
 
2.5 Benchmark Testing 
     The benchmarking of the validated source model was designed to be done in a step by step 
process with increasingly difficult treatment planning and computational challenges including 
heterogeneous media, small field sizes, and highly modulated treatment plans. The RPC’s 
anthropomorphic head and neck phantom was used in creating, delivering, and comparing to 
calculation a highly modulated, nine co-planar beam, IMRT plan to the homogenous phantom. 
Next benchmarking was done on the RPC’s heterogeneous lung phantom with first a nine co-
planar beam stereotactic body radiotherapy (SBRT) plan followed by a six co-planar, IMRT 
plan for 6MV and 10MV models, respectively. All treatment plans were designed to meet the 
credentialing criteria established by the RTOG and delivered three times to evaluate the 
repeatability. 
     The accuracy of the calculations was then assessed by comparing point doses from TLD 
measurements, and dose profiles and 2D gamma comparisons from film measurements.  
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2.5.1 Point Dose Comparisons 
     Point dose comparisons were made between calculated doses and measured TLD doses of 
the target and critical structures. The measured doses were determined from the small volume 
of TLD powder contained in the TLD capsule, and the calculated values were determined from 
a corresponding contour of the TLD in the CT scan. 
 
2.5.2 Dose Profile Comparisons 
     Dose profiles along the three primary axes and passing through the target volume were 
used as a qualitative evaluation of agreement between the source model and measurements 
performed in the phantoms. Anterior posterior (AP) and left-right (LR) profiles were extracted 
from the axial films and profiles along the superior/inferior (SI) direction were taken from the 
sagittal films. Due to the sagittal films being bisected by the axial film plane, a discontinuity in 
the center of the measured dose profile exists where the two sagittal films meet. Measured 
dose in this region should be ignored as a result. While quantitative information exists in the 
profile comparisons, the analysis was restricted to qualitative evaluation of the models’ ability to 
predict complex dose distributions. The quantitative assessment of distance to agreement was 
evaluated in the gamma analysis detailed in section 2.5.3.  
 
2.5.3 Gamma Map Comparisons 
     Two dimensional dose distributions were evaluated using the gamma index technique[68] 
as a means of evaluating the project hypothesis. Agreement between calculated and measured 
dose was evaluated in the film planes intersecting the phantom target to a criterion of ±3% of 
the target TLD dose and ±2mm distance to agreement.  
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     Exclusion of selected regions of the film were performed in areas in which discontinuities or 
alterations of the film were made to allow for proper assembly of the dosimetry tools. These 
included cut out regions of film along the central AP axis and central lateral axis of the sagittal 
and coronal films in the thorax phantom that allow for arrangement of the film along a shared 
axis, a small cutout on the right, postero-lateral corner of the axial film for the head and neck 
phantom to allow for proper placement of the film, and a cutout in the sagittal film plane to allow 
for placement of the critical structure TLD. An example from the sagittal film plane of head and 
neck phantom is included in Figure 2.3. 
 
Figure 2.3: Exclusion mask used in the evaluation of the sagittal film from the IMRT head and 
neck phantom. The exclusion areas are indicated by red lines and correspond to discontinuities 
between the superior and inferior film pieces, a cutout for the placement of the OAR TLD, and 
the pin pricks used to localize the film within the phantom insert. 
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      As a representative example of the area of the film that was evaluated, Figure 2.4 shows 
the evaluated region as dose cloud overlaid on the CT scan for the axial plane of the head and 
neck and lung phantoms, respectively. 
 
  
Figure 2.4: Region of interest evaluated using gamma analysis for the axial plane of the IMRT 
head and neck phantom (left) and lung phantom (right) is shown with the dose cloud from a 
treatment plan overlaid on the CT scan. For delineation of specific structures in the CT scan in 
each phantom see Figures 2.5 and 2.6. 
 
2.5.4 Treatment Plans 
2.5.4.1 Elekta Benchmarking 
     Treatment plans for the benchmarking of the Elekta 6MV and 10MV models were developed 
using the Pinnacle treatment planning system version 9.6 (Philips Medical Systems, Andover, 
MA). Evaluation of the dose constraints during planning were performed using Pinnacle’s 
collapsed cone convolution algorithm.  
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     The primary goal in developing the treatment plans was to increasingly challenge the dose 
calculation tool in clinically relevant ways. Because of this, there were some exceptions made 
to the planning criteria established by the RTOG and RPC in order to increase the complexity 
of the plan. For example, the planning criteria for the lung phantom can be met quite easily 
without the use of highly modulated fields. This however would not provide a satisfactory test of 
modulated fields in a heterogeneous medium for the calculation tool. As a result, modulation 
was forced in the plan at the expense of increasing the whole lung dose to a level that would 
otherwise be unacceptable in an institutional audit. 
     For the head and neck phantom, 95% of the primary PTV, constrained to the identified GTV 
in the CT scan as shown in Figure 2.5 with the OAR contours, was to receive at least 6.6Gy. 
The percentage that actually achieved this constraint was 87.4% and 90.4% for the 6MV and 
10MV plans, respectively. However the volumes receiving 6.5Gy were 98.5% and 95.9% for 
the respective plans. The secondary PTV was to receive 5.4Gy to 95% of the volume when in 
actuality the plans achieved 85.7% and 98.2%, respectively. For the 6MV plan 99.9% of the 
secondary PTV received a dose of 5.3Gy, 10cGy less than the actual requirement. The OAR 
dose was to be kept below 4.5Gy for 100% of the volume. In the actual treatment plans 0.1% 
and 0.6% received a dose of 4.5Gy. The maximum dose to normal tissue was 7.22Gy and 
7.45Gy, respectively. The total number of segments in the plan was 107 for both 6MV and 
10MV plans. While the planning criteria were not strictly met, it was decided that the levels 
achieved provided a clinically realistic enough of a plan to still test the calculation tool’s ability 
to model modulated fields in the homogenous phantom. 
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Figure 2.5: Axial (top), sagittal (bottom left), and coronal (bottom right) views of the CT scan of 
the head and neck phantom. Contours are the primary PTV (red), secondary PTV (green), and 
critical structure, the cord, (blue). The dark circles within the contours are the regions where the 
TLD are placed within the phantom and the location for point dose comparisons between 
measurement and calculation. 
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     The planning criteria for the SBRT plans on the thorax phantom were met fully. Briefly, 
97.8% and 99.4% of the PTV, defined as an expansion of 0.5cm of the GTV in the axial plane 
and 1.0cm expansion in the longitudinal plane and shown with the OAR in Figure 2.6, received 
the prescription dose for the 6MV and 10MV plans, respectively, and the maximum cord dose 
was kept to 2.0Gy and 2.2Gy, well below the 5.0Gy limit, for the respective plans. The dose to 
the heart was below 1.4Gy and 1.6Gy for the two plans. Whole lung dose was kept below 
2.0Gy for 11.7% and 13.1% of the volume for each of the plans. 
     For the IMRT plans on the lung phantom 97.0% and 96.1% of the PTV, defined in the same 
way as the SBRT plan above, met prescription for the 6MV and 10MV plans, respectively. 
Maximum dose to the cord was held at 1.8Gy for both plans, and the maximum heart dose was 
3.2Gy for 6MV and 10MV plans. The volume of the whole lung exceeding 2.0Gy was 47.8% 
and 47.4%, respectively, thus exceeding the desired maximum volume of 37%. Again, this was 
determined necessary in order to force the level of modulation desired for evaluation the model. 
The total number of segments in each plan were 45 and 44 for 6MV and 10MV plans, 
respectively. 
     Monte Carlo calculation resolution was matched to the CT voxel size. For the head and 
neck treatment plans this was 0.518 x 0.518 x 1.25 mm3, and for the lung treatment plans it 
was 1.27 x 1.27 x 1.25 mm3.  
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Figure 2.6: Axial (top), sagittal (bottom left), and coronal (bottom right) views of the CT scan of 
the thorax phantom. Contours are the PTV (green), heart (red), and the cord (blue). The dark 
circles within the contours are the regions where the TLD are placed within the phantom and 
the location for point dose comparisons between measurement and calculation. 
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2.5.4.2 Varian TrueBeam FFF Benchmarking 
     Treatment plans for the benchmarking of the Varian TrueBeam FFF 6 and FFF 10MV 
models were developed using the Eclipse treatment planning system version 11.0 (Varian 
Medical Systems, Palo Alto, CA). Evaluation of the dose constraints during planning were 
performed using Eclipse’s analytical anisotropic algorithm (AAA).  
     For the head and neck phantom, 95% of the primary PTV, constrained to the identified GTV 
in the CT scan as shown in Figure 2.3 with the OAR contours, was to receive at least 6.6Gy. 
The percentage that actually achieved this constraint was 95.5% and 94.6% for the 6MV and 
10MV plans, respectively. However the volume receiving 6.5Gy was 99.8% for the 10MV plan. 
The secondary PTV was to receive 5.4Gy to 95% of the volume when in actuality the plans 
achieved 98.2% and 94.1%, respectively. For the 10MV plan 99.3% of the secondary PTV 
received a dose of 5.3Gy, 10cGy less than the actual requirement. The OAR dose was to be 
kept below 4.5Gy for 100% of the volume. This was achieved in both plans and maximum 
doses were 4.1Gy and 3.9Gy, respectively. The maximum dose to normal tissue was 6.97Gy 
and 6.93Gy respectively. The total number of segments in each plan was 134 and 136 for 6MV 
and 10MV plans, respectively. While the planning criteria were not strictly met, it was decided 
that the levels achieved provided a clinically realistic enough of a plan to still test the calculation 
tool’s ability to model modulated fields in the homogenous phantom. 
     The achieved planning criteria for the SBRT plans on the thorax phantom were as 
prescribed with the exception of a small reduction in coverage of the PTV. Briefly, 93.8% and 
93.4% of the PTV, defined as an expansion of 0.5cm of the GTV in the axial plane and 1.0cm 
expansion in the longitudinal plane and shown with the OAR in Figure 2.4, received the 
prescription dose for the 6MV and 10MV plans, respectively, and the maximum cord dose was 
kept to 2.0Gy and 1.8Gy, well below the 5.0Gy limit, for the respective plans. The dose to the 
heart was below 2.4Gy and 2.2Gy for the two plans. Whole lung dose was kept below 2.0Gy for 
7.3% and 7.8% of the volume for each of the plans. Despite the small coverage discrepancy 
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between achieved and prescribed criteria, the plan was still judged to be an adequate test of 
the models’ performance in heterogeneous media without field modulation. 
     For the IMRT plans on the lung phantom 93.0% and 93.1% of the PTV, defined in the same 
way as the SBRT plan above. Maximum dose to the cord was held at 0.69Gy for both plans 
and the maximum heart dose was 1.2Gy for both plans. The volume of the whole lung 
exceeding 2.0Gy was 11.4% and 12.0%, respectively. The drop in coverage to the PTV for 
both plans was judged to be a result of placing the beams at purposefully challenging angles to 
increase modulation of the plan. For the purpose of testing the models’ performance, this was 
determined to be an acceptable sacrifice. The total number of segments in the plans were 63 
and 64 for 6MV and 10MV plans, respectively. 
     Calculation resolution was matched to the CT voxel size. For the head and neck treatment 
plans this was 0.68 x 0.68 x 3.00 mm3, and for the lung treatment plans it was 0.977 x 0.977 x 
3.00 mm3. 
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Chapter 3: Results and Discussion: Elekta 6MV and 10MV 
3.1 Source Model 
3.1.1 Source Model Commissioning Parameters 
     The seven optimized parameters, determined in commissioning, that describe the photon 
energy spectra, fluence contributions, and volume averaging of the ion chamber leading to an 
exaggerated penumbra for dose profiles are reported in Table 3.1 for the Elekta 6MV and 
10MV models. The first three parameters, γ, μ, and β describe the spectrum shape, peak 
energy location, and relative scale respectively.  
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Parameter 
 
Value Elekta  6MV Value Elekta  10MV 
Fatigue-Life distribution shape parameter, γ   1.79 1.15 
Fatigue-Life distribution location parameter, μ   -0.0163 -0.0165 
Fatigue-Life distribution scale parameter, β   3.69 3.95 
Primary spectrum to extra-focal spectrum reduction 
factor   1.71 3.10 
Extra-focal fluence relative to the primary fluence   0.1101 0.1901 
Electron Contamination contribution (relative to the 
primary photon contribution)   0.002 0.005 
Standard deviation of Gaussian used to convolve the 
MC dose profile to match the measured dose profile 
during validation (in mm)   1.8 1.8 
 
Table 3.1: Optimized parameters for the source models as determined during the initial 
commissioning of the models. The first three parameters describe the shape and location of the 
spectra. The fourth through sixth parameters relate the relative contribution and energy scale of 
the three sources, and the final parameter is the standard deviation of the Gaussian kernel 
convolved with the calculated dose profiles to mimic the volume averaging effect of an ion 
chamber at the penumbra of dose profiles. 
 
     A comparison of the 6MV spectrum from the optimization process and those from the widely 
accepted BEAM code[59] for simulating radiation transport in linear accelerators is show in 
Figure 3.1. In Figure 2.6 a comparison of the Elekta 10MV spectrum to the Varian 10MV 
spectrum from Davidson et. al[35] is shown. While not an exact match for either the 6MV or 
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10MV models, the results from validation indicate that it is an adequate description of the 
photon beam. The extra-focal source was scaled in energy by a factor of 1.71 and 3.10 for 6MV 
and 10MV models, respectively. Their fluences, relative to the primary point source in a 10 x 10 
cm2 open field, were found to be 11.01% and 19.01% for 6MV and 10MV models, respectively. 
The electron contamination sources, while small at 0.2% and 0.5% respectively, were still 
included in the source model, unlike the Varian 6MV model[20, 21, 35]. For the comparison of 
the dose profiles, a Gaussian kernel of standard deviation 1.8mm was convolved with the 
calculated data to model the volume averaging effect of an ion chamber measurement. 
 
Figure 3.1: Comparison of commissioned Elekta 6MV source model spectrum with the results 
from BEAM (Sheikh-Bagheri and Rogers) and Davidson et. al. 
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Figure 3.2: Comparison of commissioned Elekta 10MV source model spectrum with the results 
from Davidson et. al. 
 
     The results to the second step of the commissioning process in which the off-axis fluence 
was modeled by a piecewise linear function of the cosine of the off-axis angle are shown in 
Table 3.2. The off-axis energy correction was implemented from Tailor et al. [61] without 
change.  
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Cosine (Off-axis Angle) 
  Fluence Weight (Relative to CAX) Fluence Weight (Relative to CAX) 
  Elekta 6MV Model Elekta 10 MV Model 
1.00000 
 
1.0000 1.0000 
0.99970 
 
1.0390 1.0310 
0.99789 
 
1.0488 1.0620 
0.99728 
 
1.0880 1.0980 
0.99518 
 
1.1251 1.1300 
0.99250 
 
1.1687 1.1700 
0.98926 
 
1.2143 1.2000 
0.98546 
 
1.2245 1.2200 
0.98113 
 
1.2619 1.2300 
0.97630 
 
1.2933 1.2800 
0.97098 
 
1.3193 1.3000 
0.96277   1.3528 1.3200 
 
Table 3.2: Optimized coefficients to a piece-wise linear function used to describe the increase 
in off-axis fluence of Elekta 6MV and 10MV models. Fluence weighting values are reported with 
respect to the dose measured at the central axis (CAX) for the 40 x 40 cm2 field size dose 
profile at a depth of dmax. 
 
     After completing the second step of the commissioning process, the scaling factor used to 
convert the Monte Carlo output from energy per particle to cGy per MU was determined from 
the dose at dmax along the central axis for a 10 x 10 cm
2 field size. These values were 25.17 
and 15.92 for the 6MV and 10MV models, respectively. This factor will be applied to all 
subsequent dose calculations for the corresponding linac/energy models. 
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3.1.2 Fluence Map, Primary Source Size, and Machine Output Correction 
     Fluence map generation is a process that is unique to the treatment plan, patient, phantom, 
or open field delivery, and beam energy. The MLC positions for each segment weight the 
fluence by assuming 1% transmission through the leaves and an additional 1% as interleaf 
leakage. The transmission and the leakage percentages were the same for 6MV and 10MV 
models. 
     Because the source model includes a point source representing photons created within the 
target and not a finite source size, an offset of the MLC, xpen, of 0.4mm was necessary. This 
was the same offset used in the Varian model[20, 21, 35] and because the literature has 
suggested its size is nearly fixed for different nominal energies from the same 
manufacturer[69], it was left constant for both 6MV and 10MV models. 
     An empirically determined field size dependent output correction was implemented in 
addition to the normal output factor due to the models inability to fully model field size 
dependent scatter conditions. Each model, Elekta 6MV (equation 3.1) and 10MV (equation 
3.2), had its own correction implemented.  
 
Elekta 6MV Output Correction 
        
    
      
      (3.1) 
 
Elekta 10MV Output Correction 
        
    
      
      (3.2) 
 
In the above equations, y is the output correction and x is the field size. Graphs of the 
measured and uncorrected and corrected data are shown below in Figure 3.3 and Figure 3.4.  
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Figure 3.3: Output at a depth of 1.6cm for the measured data (blue circles), calculated data 
without the hyperbolic correction (red star), and the calculated data with the hyperbolic 
correction (green x) for the Elekta 6MV source model.  
 Figure 3.4: Output at a depth of 2.0cm for the measured data (blue circles), calculated data 
without the hyperbolic correction (red star), and the calculated data with the hyperbolic 
correction (green triangle) for the Elekta 10MV source model.  
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3.2 Validation Testing 
3.2.1 Uncertainty 
     The uncertainty in the ion chamber measurements was estimated at 1.6% (one standard 
deviation) to match that reported in the literature[70]. The standard error of the mean in the 
dose calculations was calculated to be no more than 2.5% using the batch method described in 
AAPM Task Group Report No. 105[22].   
 
3.2.2 Depth Dose Data 
     The comparison between measured and calculated depth dose data for the Elekta 6MV and 
10MV models was performed for field sizes ranging from 3 x 3 cm 2 to 30 x 30 cm2. Gamma 
analysis agreement using a ±2%/2mm criterion is summarized in Table 2.3. The percentage of 
data passing the criterion for every field size at every depth is reported in the Appendix 
(Chapter 6). For a graphical comparison between depth dose data of all field sizes please see 
the Appendix (Chapter 6). As representative summary the smallest (3 x 3 cm 2), nominal (10 x 
10 cm2), and largest (30 x 30 cm2) field sizes are shown for the Elekta 6MV model in Figures 
3.5, 3.6, and 3.7, respectively. The same field sizes are shown for the Elekta 10MV model in 
Figure 3.8, 3.9, and 3.10, respectively. 
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Validation Results –Depth Dose Data 
Field Size (cm2) 
% Pixels Passing 
Elekta 6MV Model Elekta 10MV Model 
3 x 3 99.4 99.4 
5 x 5 99.4 99.4 
10 x 10 100.0 99.4 
15 x 15 100.0 100.0 
20 x 20 99.4 100.0 
30 x 30 99.4 100.0 
Table 3.3: Gamma comparison agreement for Elekta 6MV and 10MV models using a 
±2%/2mm criterion for measured and calculated depth dose data 
 
 
Figure 3.5: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 6MV 
beam for a 3 x 3 cm 2 field size. Gamma agreement (red circles) for each point is also 
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion. 
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Figure 3.6: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 6MV 
beam for a 10 x 10 cm2 field size. Gamma agreement (red circles) for each point is also 
displayed. There were no failures for this field size and as a result no failure points marked. 
 
 
Figure 3.7: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 6MV 
beam for a 30 x 30 cm2 field size. Gamma agreement (red circles) for each point is also 
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion. 
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Figure 3.8: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 
10MV beam for a 3 x 3 cm 2 field size. Gamma agreement (red circles) for each point is also 
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion. 
 
 
Figure 3.9: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 
10MV beam for a 10 x 10 cm2 field size. Gamma agreement (red circles) for each point is also 
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion. 
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Figure 3.10: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 
10MV beam for a 30 x 30 cm2 field size. Gamma agreement (red circles) for each point is also 
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion. 
 
 
3.2.3 Dose Profiles 
     A comparison of calculated dose profiles to measurements was performed for both Elekta 
6MV and 10MV models at depths of dmax, 5cm, 10cm, and 20cm for field sizes ranging from 3 x 
3 cm 2 to 30 x 30 cm2. An additional comparison at depths of 25cm was performed for the 
Elekta 10MV model. Gamma analysis with ±2%/2mm criteria was used as the means of 
comparison and is summarized in Table 3.4. The percentages of pixels passing for each profile 
compared are reported in the Appendix (Chapter 6) along with graphs of each comparison. As 
a representative summary the smallest (3 x 3 cm 2), nominal (10 x 10 cm2), and largest (30 x 30 
cm2) field sizes are shown for the Elekta 6MV model in Figures 3.11, 3.12, and 3.13, 
respectively. The same field sizes are shown for the Elekta 10MV model in Figure 3.14, 3.15, 
and 3.16, respectively. 
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     As can be seen in Figures 3.11 through 3.16, comparisons were performed on both in-plane 
and cross-plane profiles. The Monte Carlo model however assumes an equal distance from the 
target for the x-jaws and y-jaws resulting in identical calculated dose profiles for in-plane and 
cross-plane. As a result, the overlapping calculated data appears as a single profile in the 
comparisons. The Appendix reports the agreement along both directions, and based on the 
observed agreement of these results it was decided the assumption of the model was 
reasonable. 
 
 
Figure 3.11: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
6MV beam at a field size of 3 x 3 cm 2.  
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Figure 3.12: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
6MV beam at a field size of 10 x 10 cm2. 
 
 
Figure 3.13: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
6MV beam at a field size of 30 x 30 cm2. 
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Figure 3.14: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 3 x 3 cm 2. 
 
 
Figure 3.15: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 10 x 10 cm2. 
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Figure 3.16: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 30 x 30 cm2. 
 
     Agreement between calculated and measured profile data was assessed using the gamma 
technique with an evaluation criterion of ±2%/2mm. Profiles at all field sizes and depths 
showed excellent agreement with the minimum percentage of pixels passing each individual 
profile being 94.8% and 91.0% for 6MV and 10MV models, respectively. The average 
percentage of pixels passing the gamma analysis was 99.4% and 99.6% for 6MV and 10MV 
models respectively. Table 3.4 displays the average agreement by field size for both 6MV and 
10MV models. 
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Validation Results – Dose Profile Data 
Field Size (cm2) 
% Pixels Passing 
Elekta 6MV Model Elekta 10MV Model 
3 x 3 99.0 99.6 
5 x 5 99.5 100.0 
10 x 10 99.5 100.0 
15 x 15 99.4 99.5 
20 x 20 99.8 99.9 
30 x 30 99.4 99.9 
Table 3.4: Gamma comparison agreement for Elekta 6MV and 10MV models using a 
±2%/2mm criterion for measured and calculated dose profile data. Dose profiles were 
measured and calculated in-plane and cross-plane at depths of dmax (1.6cm for 6MV and 2.0cm 
for 10MV), 5cm, 10cm, 20cm, and 25cm (10MV only).  
 
3.3 Benchmark Testing 
3.3.1 Uncertainty 
     The measurement uncertainty in the dose distributions in the radiochromic film, normalized 
to the adjacent TLD doses, was estimated in previous studies to be between 2.6% and 3.5% at 
one standard deviation[12, 35]. By normalizing the film to the TLD dose, the uncertainty related 
to differences between the film calibration process and the actual film used in benchmarking 
was minimized. The literature details the estimated uncertainty of the TLD dose[11], the film 
uniformity, film-to-film variation, and the fit of the sensitometric curve[71]. 
     The estimated single voxel standard error of the mean in the phantom plan simulations was 
1.1% using 12 million particles per square centimeter.   
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3.3.2 Deliver of IMRT H&N Phantom Plan: Point Dose Comparison 
     Results comparing TLD measurements to predicted doses by the multiple source model are 
shown in Table 3.5 for the Elekta 6MV model and Table 3.6 for the Elekta 10MV model. TLD 
capsules were contained within the center of the primary PTV (four capsules), center of the 
secondary PTV (two capsules) and the center of a mock organ at risk (two capsules). Included 
in the table are average dose measurements, percent standard deviation from the three 
deliveries of each plan, a comparison of the DPM predicted dose with measurement expressed 
as a ratio of calculated dose to measured dose, and, for reference, a comparison of Pinnacle 
calculated dose with measurement expressed as a ratio of calculated to measured dose.  
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TLD 
Measurement DPM Calculation Pinnacle Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Pri – SP 644.7 0.7 672.5 1.9 1.043 667.8 0.7 1.036 
Pri – SA 654.9 0.1 655.1 1.9 1.000 666.6 0.7 1.018 
Pri – IP 634.9 0.7 649.4 2.1 1.023 664.7 0.6 1.047 
Pri –IA 646.3 0.7 638.6 2.0 0.988 664.9 0.7 1.029 
Pri Avg. 
    
1.014 
  
1.032 
Sec – S 527.3 0.4 529.6 1.4 1.004 542.1 0.5 1.028 
Sec – I 523.6 0.1 521.6 2.0 0.996 542.1 0.2 1.035 
Sec Avg. 
    
1.000 
  
1.032 
OAR – S 277.1 0.2 288.2 11.7 1.040 316.7 1.3 1.143 
OAR – I 294.6 0.4 304.5 10.0 1.033 339.0 1.4 1.151 
OAR Avg. 
    
1.037 
  
1.147 
 
Table 3.5: Point dose comparisons for the Elekta 6MV IMRT head and neck phantom 
measurements. The measured dose is the averaged dose from the three deliveries of each 
plan. Comparison to calculated doses by DPM (left) and Pinnacle (right) are expressed as a 
ratio of calculated to measured doses. Point dose locations are indicated by Pri = Primary PTV, 
Sec = Secondary PTV, OAR = Organ at Risk, S = Superior, I = Inferior, A = Anterior, P = 
Posterior. 
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     For the Elekta 6MV model the average agreement between the DPM multiple source model 
calculation and measurement in the primary PTV was 1.014. The range of calculated to 
measured dose ratios was from 0.988 to 1.043. The secondary PTV showed an average 
agreement of 1.000 with a range from 0.996 to 1.004. The averaged ratio for the OAR TLD was 
1.037 with a range of 1.033 to 1.040. The poorer agreement with the OAR measured dose 
could largely be attributed to the high dose gradient in the region due to the OAR’s close 
proximity to the primary PTV. 
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  TLD Measurement DPM Calculation Pinnacle Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Pri – SP 625.1 0.4 676.8 2.0 1.083 677.0 0.8 1.083 
Pri – SA 657.2 0.3 645.2 1.7 0.982 672.7 1.5 1.024 
Pri – IP 639.4 0.2 658.2 1.7 1.029 676.3 0.7 1.058 
Pri –IA 662.1 0.8 653.4 2.1 0.987 686.7 0.7 1.037 
Pri Avg. 
    
1.020 
  
1.050 
Sec – S 531.0 0.5 529.4 1.4 0.997 550.8 0.0 1.037 
Sec – I 526.8 0.7 520.2 1.0 0.987 551.0 0.0 1.046 
Sec Avg. 
    
0.992 
  
1.042 
OAR – S 252.9 0.9 288.9 7.9 1.142 307.4 0.4 1.216 
OAR – I 260.5 0.6 297.4 6.2 1.141 321.5 0.3 1.234 
OAR Avg. 
    
1.142 
  
1.225 
 
Table 3.6: Point dose comparisons for the Elekta 10MV IMRT head and neck phantom 
measurements. The measured dose is the averaged dose from the three deliveries of each 
plan. Comparison to calculated doses by DPM (left) and Pinnacle (right) are expressed as a 
ratio of calculated to measured doses. Point dose locations are indicated by Pri = Primary PTV, 
Sec = Secondary PTV, OAR = Organ at Risk, S = Superior, I = Inferior, A = Anterior, P = 
Posterior. 
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     Results for the Elekta 10MV model show an average agreement between the DPM code 
and measurement in the primary PTV of 1.020. The range contributing to this average was 
from 0.982 to 1.083. The poor agreement seen in the superior posterior TLD is suspected to be 
due to its proximity to a high dose gradient. Further examination of the dose field showed that a 
setup error as small as 1.5mm could contribute to the 8% change in dose. Agreement in the 
secondary PTV was 0.992 with a range of 0.987 to 0.997. Comparisons in the OAR showed an 
average agreement of 1.142 with a range of 1.141 to 1.142. Similar to the 6MV model, the OAR 
showed an overall poorer agreement with measurement. This was again attributed to the high 
dose gradient in the region.  
      While the benchmarking of the multiple source model was based exclusively on 
measurement, comparisons to doses calculated by Pinnacle are included as means of 
comparison against an actively used and state of the art treatment planning system dose 
calculation algorithm. A comparison between average agreement of DPM to measured doses 
and Pinnacle to measured doses shows superior performance for the Monte Carlo based 
calculation technique. 
 
3.3.3 Delivery of IMRT H&N Phantom Plan: Dose Profile and Gamma Map Comparison 
     Dose profile comparison between the multiple source model and measurement are shown 
for all three major planes in Figures 3.17, 3.18, 3.19 for the 6MV model and Figures 3.20, 3.21, 
and 3.22 for the 10MV model. These comparisons are meant to be a qualitative assessment of 
the models ability to predict complex dose distributions across the volume of the PTV. All 
profiles showed good agreement between calculation and measurement. 
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Figure 3.17: A comparison of the lateral (left to right) profile from the axial film of an IMRT H&N 
delivery for the 6MV model (delivery #1). 
 
 
Figure 3.18: A comparison of the AP (anterior to posterior) profile from the axial film of an 
IMRT H&N delivery for the 6MV model (delivery #1). 
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Figure 3.19: A comparison of the SI (superior to inferior) profile from the axial film of an IMRT 
H&N delivery for the 6MV model (delivery #1). 
 
 
Figure 3.20: A comparison of the lateral (left to right) profile from the axial film of an IMRT H&N 
delivery for the 10MV model (delivery #1). 
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Figure 3.21: A comparison of the AP (anterior to posterior) profile from the axial film of an 
IMRT H&N delivery for the 10MV model (delivery #1). 
 
Figure 3.22: A comparison of the SI (superior to inferior) profile from the axial film of an IMRT 
H&N delivery for the 10MV model (delivery #1). 
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     To evaluate the models performance at describing the penumbra, MLC leakage, rounded 
leaf tips, and leaf transmission in highly modulated fields, gamma analysis was performed 
using a ±3%/2mm criterion. The analysis considers dose differences as relative percentage 
and the distance to agreement to assess overall agreement and identify locations of difficulty to 
the model. The resulting gamma maps from a single irradiation in the axial and sagittal plans 
are shown in Figure 3.23 and Figure 3.24 for the 6MV model and Figure 3.25 and Figure 3.26 
for the 10MV model. Gamma maps for all three deliveries of each nominal energy are included 
in the Appendix. For the IMRT head and neck plan, the average percent of pixels passing for 
the 6MV comparison was 87.2% with a range of 82.5% to 91.4%. The 10MV comparison 
averaged 90.5% of pixels passing the ±3%/2mm criterion with a range of 86.4% to 95.9%. 
Table 3.7 reports the average agreement in the sagittal and axial planes for both the 6MV and 
10MV models. 
 
 
Elekta 6MV Elekta 10MV 
  Axial Sagittal Axial Sagittal 
Delivery #1 91.4 88.9 91.3 87.9 
Delivery #2 87.6 86.7 91.6 86.4 
Delivery #3 82.5 86.1 95.9 87.3 
Average 87.2 87.3 92.9 87.2 
 
Table 3.7: Percentage of pixels passing a ±3%/2mm gamma criterion for IMRT head and neck 
plans for both Elekta 6MV and 10MV models. Agreement was evaluated in both the axial and 
sagittal planes for three deliveries of each plan. 
 
56 
 
 
Figure 3.23: IMRT head and neck delivery comparison for the axial plane of delivery #1 for the 
Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 91.4% of 
pixels passed.  
 
Figure 3.24: IMRT head and neck delivery comparison for the sagittal plane of delivery #1 for 
the Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
88.9% of pixels passed.  
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Figure 3.25: IMRT head and neck delivery comparison for the axial plane of delivery #3 for the 
Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 95.9% 
of pixels passed.  
 
Figure 3.26: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for 
the Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
87.3% of pixels passed.  
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     Qualitative evaluation of the axial gamma maps revealed no consistent failure regions in the 
dose distribution for either the 6MV or 10MV comparisons. Failure regions of the sagittal 
gamma maps were consistently along the posterior edge of the PTV in the superior film piece 
for both 6MV and 10MV comparisons. This is largely attributed to the sensitivity of the 
comparison to the registration of film to the phantom. Because the sagittal comparisons consist 
of two pieces of film that need to be aligned during scanning, the registration uncertainty is 
higher than for the axial plane which consists of single piece of film. Dose profiles shown in 
Figure 3.27 suggest that there could be an approximately 1mm offset in the alignment of the 
superior piece of film with respect to the inferior piece of film. Even with the increased 
registration uncertainty, passing rates were above the pre-established threshold of 85%. 
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Figure 3.27: Dose profile comparison for IMRT head and neck delivery for 10MV Elekta model. 
The top profile is along the anteroposterior direction of the superior film piece, and the bottom 
is along the anteroposterior direction of the inferior film piece. 
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3.3.4 Delivery of SBRT Thorax Phantom Plan: Point Dose Comparison 
     The results to point dose comparisons between the developed model and TLD 
measurements in the anthropomorphic thorax phantom are shown in Table 3.8 and Table 3.9. 
Double packed TLD were contained in the center of the target (two), in the heart (one), and in 
the spinal cord (one). The table includes average dose measurements, percent standard 
deviation from the three deliveries of each plan, a comparison of the DPM predicted dose with 
measurement expressed as a ratio of calculated dose to measured dose, and, for reference, a 
comparison of Pinnacle calculated doses with measurement expressed as a ratio of measured 
to calculated dose. 
 
 
TLD 
Measurement DPM Calculation Pinnacle Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
PTV – S 657.6 0.4 677.2 0.7 1.030 658.0 3.0 1.001 
PTV – I 659.8 0.3 679.1 0.7 1.029 661.7 2.8 1.003 
PTV Avg. 
    
1.030 
  
1.002 
OAR – Heart 99.0 0.2 107.4 2.1 1.085 99.6 5.8 1.006 
OAR – Cord 122.6 0.4 130.3 1.8 1.062 136.8 2.4 1.115 
 
Table 3.8: Point dose comparisons for the Elekta 6MV SBRT lung phantom measurements. 
The measured dose is the averaged dose from the three deliveries of each plan. Comparison 
to calculated doses by DPM (left) and Pinnacle (right) are expressed as a ratio of calculated to 
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR = 
Organ at Risk, S = Superior, I = Inferior. 
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     For the Elekta 6MV model the average agreement between the DPM multiple source model 
calculation and measurement in the PTV was 1.030. The range of calculated to measured dose 
ratios was from 1.029 to 1.030. The ratio for the heart TLD was 1.085, and the ratio for the cord 
TLD was 1.062.  
 
  TLD Measurement DPM Calculation Pinnacle Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
PTV – S 664.5 0.2 679.1 1.0 1.022 672.8 3.1 1.012 
PTV – I 675.0 0.7 681.6 0.8 1.010 674.9 3.1 1.000 
PTV Avg. 
    
1.016 
  
1.006 
OAR – Heart 99.1 0.2 105.2 4.1 1.061 100.5 7.1 1.014 
OAR – Cord 122.5 0.8 130.0 0.0 1.061 136.2 2.9 1.112 
 
Table 3.9: Point dose comparisons for the Elekta 10MV SBRT lung phantom measurements. 
The measured dose is the averaged dose from the three deliveries of each plan. Comparison 
to calculated doses by DPM (left) and Pinnacle (right) are expressed as a ratio of calculated to 
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR = 
Organ at Risk, S = Superior, I = Inferior. 
 
     The average agreement between the DPM model and the PTV for the Elekta 10MV model 
was 1.016. The range of the values for the PTV agreement was from 1.010 to 1.022. The 
calculated to measured ratio for both the heart and cord TLDs was 1.061. 
     It is important to note that while the OAR calculated doses showed poorer agreement with 
measurements for 6MV and 10MV models, the uncertainty in the measured dose is unknown at 
such low doses. The standards used for low dose measurements are done at doses of 8Gy 
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and 3Gy, nearly 3 times the dose of both the heart and cord measurement for the lower of the 
two standard doses. At doses near 1Gy, as seen in both of the OAR TLD, the RPC does not 
have data documenting the accuracy of their TLD measurement process for phantom 
irradiations. 
     Even though the benchmarking of the multiple source model was based exclusively on 
measurement, comparisons to doses calculated by Pinnacle are included as means of 
comparison against an actively used and state of the art treatment planning system dose 
calculation algorithm. A direct comparison between the DPM calculated doses and the Pinnacle 
calculated doses show the DPM calculation to be comparable with measurement results in the 
OARs and within the PTVs. 
 
3.3.5 Delivery of SBRT Thorax Phantom Plan: Dose Profile and Gamma Map Comparison 
     Dose profile comparison between the multiple source model and measurement are shown 
for all three major planes in Figures 3.28, 3.29, 3.30 for the 6MV model and Figures 3.31, 3.32, 
and 3.33 for the 10MV model. These comparisons are meant to be a qualitative assessment of 
the models ability to predict complex dose distributions across the volume of the PTV. All 
profiles showed good agreement between calculation and measurement. 
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Figure 3.28: A comparison of the lateral (left to right) profile from the axial film of an SBRT lung 
delivery for the 6MV model (delivery #1). 
 
 
 
Figure 3.29: A comparison of the AP (anterior to posterior) profile from the axial film of an 
SBRT lung delivery for the 6MV model (delivery #1). 
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Figure 3.30: A comparison of the SI (superior to inferior) profile from the sagittal film of an 
SBRT lung delivery for the 6MV model (delivery #1). 
 
 
Figure 3.31: A comparison of the lateral (left to right) profile from the axial film of an SBRT lung 
delivery for the 10MV model (delivery #1). 
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Figure 3.32: A comparison of the AP (anterior to posterior) profile from the axial film of an 
SBRT lung delivery for the 10MV model (delivery #1). 
 
 
Figure 3.33: A comparison of the SI (superior to inferior) profile from the sagittal film of an 
SBRT lung delivery for the 10MV model (delivery #1). 
 
     The models ability to describe the beam penumbra, MLC leakage, rounded leaf tips, and 
leaf transmission in unmodulated fields in a heterogeneous medium provided by the lung 
phantom was evaluated using the gamma technique with a ±3%/2mm criterion. The analysis 
considers the dose differences as a percentage of the maximum dose and distance to 
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agreement to assess overall agreement between dose distributions calculated by the multiple 
source model and measured by the radiochromic film in the phantom. In this way resulting 
gamma maps can be used to identify areas where the model may be deficient while allowing 
for positional measurement uncertainty to be accounted for in the distance to agreement 
criterion.  
     The gamma maps for a single irradiation and comparison to source model calculation for the 
6MV model are showing in Figures 3.34, 3.35, and 3.36 for the axial, sagittal, and coronal 
planes respectively. Gamma maps for each delivery are included in the Appendix. The average 
agreement, expressed as a percentage of pixels passing the gamma criterion, were 86.8%, 
86.9%, and 87.8% for axial, sagittal, and coronal planes, respectively. Agreement for the axial 
plane ranged from 85.3% to 89.0%. Agreement for the sagittal plane ranged from 85.9% to 
87.7%, and the range of agreement for the coronal plane was 84.2% to 93.9%.  
 
Figure 3.34: Lung SBRT delivery comparison for the axial plane of delivery #1 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.3% of pixels 
passed.  
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Figure 3.35: Lung SBRT delivery comparison for the sagittal plane of delivery #1 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 87.7% of pixels 
passed.  
 
Figure 3.36: Lung SBRT delivery comparison for the coronal plane of delivery #1 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 93.9% of pixels 
passed. 
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     The gamma maps corresponding to the comparison of a single irradiation to the calculated 
dose of the 10MV source model are showing in Figures 3.37, 3.38, and 3.39 for axial, sagittal, 
and coronal planes, respectively. Gamma maps from all other deliveries are included in the 
Appendix for reference. The average agreement was 90.2%, 88.3%, and 89.5% for axial, 
sagittal, and coronal planes, respectively. The range of values for the axial plane was 86.2% to 
96.5%, for the sagittal plane 85.2% to 90.8%, and for the coronal plane 85.3% to 92.6%. 
 
 
Figure 3.37: Lung SBRT delivery comparison for the axial plane of delivery #1 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 96.5% of 
pixels passed. 
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Figure 3.38: Lung SBRT delivery comparison for the sagittal plane of delivery #1 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.1% of 
pixels passed.  
 
Figure 3.39: Lung SBRT delivery comparison for the coronal plane of delivery #1 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 92.6% of 
pixels passed. 
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     The passing rate of comparisons for each plane for all three deliveries with respect to the 
DPM source model calculation is shown for both 6MV and 10MV models in Table 3.10.  
  Elekta 6MV Elekta 10MV 
  Axial Sagittal Coronal Axial Sagittal Coronal 
Delivery #1 85.3 87.7 93.9 96.5 89.1 92.6 
Delivery #2 86.2 85.9 85.3 86.2 90.8 85.3 
Delivery #3 89.0 87.0 84.2 88.1 85.2 90.5 
Average 86.8 86.9 87.8 90.2 88.3 89.5 
 
Table 3.10: Percentage of pixels passing a ±3%/2mm gamma criterion for SBRT lung plans for 
both Elekta 6MV and 10MV models. Agreement was evaluated in the axial, sagittal, and 
coronal planes for three deliveries of each plan. 
 
     A qualitative evaluation of the gamma maps showed no consistent failure regions in the 
comparison in the axial plane. The agreement in the sagittal and coronal planes appeared to be 
challenged most at the edges of the PTV. This is largely attributed to the sensitivity of the 
comparison to the registration of film to the phantom. Because both film plane comparisons 
consist of two pieces of film that need to be aligned during scanning, the registration 
uncertainty is higher than for the axial plane which consists of single piece of film. Furthermore 
the high dose gradients at the edges of the PTV make the analysis more sensitive to a small 
translational shift either in the film registration or phantom setup. Even with the increased 
registration uncertainty, passing rates were above the pre-established threshold of 85%. 
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3.3.6 Delivery of IMRT Thorax Phantom Plan: Point Dose Comparison 
     The results of the point dose comparisons between the developed model and TLD 
measurements in the anthropomorphic thorax phantom are shown in Table 3.11 and Table 
3.12. Double packed TLD were contained in the center of the target (two), in the heart (one), 
and in the spinal cord (one). The table includes dose measurements, a comparison of the DPM 
predicted dose with measurement expressed as a ratio of calculated dose to measured dose, 
and, for reference, a comparison of Pinnacle calculated doses with measurement expressed as 
a ratio of measured to calculated dose. 
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TLD 
Measurement DPM Calculation Pinnacle Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
PTV – S 611.9 0.4 614.0 0.7 1.003 611.9 0.5 1.000 
PTV – I 607.9 0.4 610.5 0.3 1.004 608.2 0.5 1.000 
PTV Avg. 
    
1.004 
  
1.000 
OAR – Heart 98.1 0.8 90.0 0.0 0.917 94.9 3.7 0.967 
OAR – Cord 221.7 0.4 227.0 1.8 1.024 212.8 6.9 0.960 
 
Table 3.11: Point dose comparisons for the Elekta 6MV IMRT lung phantom measurements. 
The measured dose is the averaged dose from the three deliveries of each plan. Comparison 
to calculated doses by DPM (left) and Pinnacle (right) are expressed as a ratio of calculated to 
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR = 
Organ at Risk, S = Superior, I = Inferior. 
 
     For the Elekta 6MV model the average agreement between the DPM multiple source model 
calculation and measurement in the PTV was 1.004. The range of calculated to measured dose 
ratios within the PTV was 1.003 to 1.004. The ratio for the heart TLD was 0.917, and the ratio 
for the cord TLD was 1.024.  
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  TLD Measurement DPM Calculation Pinnacle Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
PTV – S 594.6 0.4 608.4 1.6 1.023 622.8 0.6 1.047 
PTV – I 591.4 0.1 602.2 0.8 1.018 613.8 0.6 1.038 
PTV Avg. 
    
1.021 
  
1.043 
OAR – Heart 95.8 0.3 90.0 0.0 0.940 97.5 3.0 1.018 
OAR – Cord 242.5 0.5 234.8 6.4 0.968 234.6 7.6 0.967 
 
Table 3.12: Point dose comparisons for the Elekta 10MV IMRT lung phantom measurements. 
The measured dose is the averaged dose from the three deliveries of each plan. Comparison 
to calculated doses by DPM (left) and Pinnacle (right) are expressed as a ratio of calculated to 
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR = 
Organ at Risk, S = Superior, I = Inferior. 
 
     The average agreement between the DPM model and the PTV for the Elekta 10MV model 
was 1.021. The range of the values for the PTV agreement was from 1.018 to 1.023. The 
calculated to measured ratio for the heart and cord TLDs were 0.940 and 0.968, respectively. 
     It is important to note that while the OAR calculated doses showed poorer agreement with 
measurements for 6MV and 10MV models, the uncertainty in the measured dose is unknown at 
such low doses. The standards used for low dose measurements are done at doses of 8Gy 
and 3Gy, nearly 3 times the dose of both the heart and cord measurement for the lower of the 
two standard doses. At doses near 1Gy, as seen in both of the OAR TLD, the RPC does not 
have data documenting the accuracy of their TLD measurement process for phantom 
irradiations. 
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     Even though the benchmarking of the multiple source model was based exclusively on 
measurement, comparisons to doses calculated by Pinnacle are included as means of 
comparison against an actively used and state of the art treatment planning system dose 
calculation algorithm. A direct comparison between the DPM calculated dose performance to 
the Pinnacle calculated dose performance shows superior results in the PTV TLD capsules and 
comparable performance within the OARs. 
 
3.3.7 Delivery of IMRT Thorax Phantom Plan: Dose Profile and Gamma Map Comparison 
     Dose profile comparison between the multiple source model and measurement are shown 
for all three major planes in Figures 3.40, 3.41, 3.42 for the 6MV model and Figures 3.43, 3.44, 
and 3.45 for the 10MV model. These comparisons are meant to be a qualitative assessment of 
the models ability to predict complex dose distributions across the volume of the PTV. All 
profiles showed good agreement between calculation and measurement. 
 
 
Figure 3.40: A comparison of the lateral (left to right) profile from the axial film of an IMRT lung 
delivery for the 6MV model. 
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Figure 3.41: A comparison of the AP (anterior to posterior) profile from the axial film of an 
IMRT lung delivery for the 6MV model. 
 
 
Figure 3.42: A comparison of the SI (superior to inferior) profile from the coronal film of an 
IMRT lung delivery for the 6MV model. 
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Figure 3.43: A comparison of the lateral (left to right) profile from the axial film of an IMRT lung 
delivery for the 10MV model. 
 
 
Figure 3.44: A comparison of the AP (anterior to posterior) profile from the axial film of an 
IMRT lung delivery for the 10MV model. 
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Figure 3.45: A comparison of the SI (superior to inferior) profile from the coronal film of an 
IMRT lung delivery for the 10MV model. 
 
     The models ability to describe the beam penumbra, MLC leakage, rounded leaf tips, and 
leaf transmission in unmodulated fields in a heterogeneous medium provided by the lung 
phantom was evaluated using the gamma technique with a ±3%/2mm criterion. The analysis 
considers the dose differences as a percentage of the maximum dose and distance to 
agreement to assess overall agreement between dose distributions calculated by the multiple 
source model and measured by the radiochromic film in the phantom. In this way resulting 
gamma maps can be used to identify areas where the model may be deficient while allowing 
for positional measurement uncertainty to be accounted for in the distance to agreement 
criterion.  
     The gamma maps and comparison to source model calculation for the 6MV model are 
showing in Figures 3.46, 3.47, and 3.48 for the axial, sagittal, and coronal planes respectively. 
The agreement, expressed as a percentage of pixels passing the gamma criterion, were 
85.2%, 90.0%, and 88.6% for axial, sagittal, and coronal planes, respectively. The individual 
passing rates for each film plane in each deliver are presented in Table 3.12. 
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Figure 3.46: Lung IMRT delivery comparison for the axial plane of delivery #3 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 87.5% of pixels 
passed.  
 
Figure 3.47: Lung IMRT delivery comparison for the sagittal plane of delivery #3 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 86.4% of pixels 
passed.  
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Figure 3.48: Lung IMRT delivery comparison for the coronal plane of delivery #3 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 94.0% of pixels 
passed. 
 
     The gamma maps corresponding to the comparison of a single irradiation to the calculated 
dose of the 10MV source model are shown in Figures 3.49, 3.50, and 3.51 for axial, sagittal, 
and coronal planes, respectively. The agreement was 91.2%, 90.6%, and 88.0% for axial, 
sagittal, and coronal planes, respectively. Individual passing rates for each plane in each 
delivery are presented in Table 3.13. 
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  Elekta 6MV Elekta 10MV 
  Axial Sagittal Coronal Axial Sagittal Coronal 
Delivery #1 82.6 92.5 89.8 94.7 90.6 89.29 
Delivery #2 85.4 83.5 89.8 86.6 87.3 86.03 
Delivery #3 87.5 94.0 86.4 92.5 94.0 88.53 
Average 85.2 90.0 88.6 91.2 90.6 88.0 
 
Table 3.13: Percentage of pixels passing a ±3%/2mm gamma criterion for IMRT lung plans for 
both Elekta 6MV and 10MV models. Agreement was evaluated in the axial, sagittal, and 
coronal planes for three deliveries of each plan. 
 
 
Figure 3.49: Lung IMRT delivery comparison for the axial plane of delivery #1 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 94.7% of 
pixels passed.  
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Figure 3.50: Lung IMRT delivery comparison for the sagittal plane of delivery #1 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 90.6% of 
pixels passed.  
 
 
Figure 3.51: Lung IMRT delivery comparison for the coronal plane of delivery #1 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.3% of 
pixels passed. 
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     A qualitative evaluation of the gamma maps showed no consistent failure regions in the 
comparison in the axial plane. The agreement in the sagittal and coronal planes appeared to be 
challenged most at the edges of the PTV. This is largely attributed to the sensitivity of the 
comparison to the registration of film to the phantom. Because both film plane comparisons 
consist of two pieces of film that need to be aligned during scanning, the registration 
uncertainty is higher than for the axial plane which consists of single piece of film. Furthermore 
the high dose gradients at the edges of the PTV make the analysis more sensitive to a small 
translational shift either in the film registration or phantom setup. Even with the increased 
registration uncertainty, passing rates were above the pre-established threshold of 85%. 
 
3.3.8 Benchmark Summary 
     The average and range of the percent of pixels passing a ±3%/2mm global gamma criterion 
for each phantom for both Elekta 6MV and 10MV source models is presented in Table 3.14.  
 
    IMRT H&N SBRT Lung IMRT Lung 
Elekta 
6MV 
Average 87.2 87.2 87.9 
Range 82.5 – 91.4 84.2 – 93.9 82.6 – 94.0 
Elekta 
10MV 
Average 90.5 89.3 89.9 
Range 86.4 – 95.9 85.2 – 96.5 86.0 – 94.7 
 
Table 3.14: The average and range of the percent of pixels passing a ±3%/2mm gamma 
criterion for Elekta 6MV and 10MV source models as assessed through three repeated 
deliveries for three different treatment plans to anthropomorphic phantoms.  
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     Each multiple source model was benchmarked against three progressively challenging 
treatment plans delivered to anthropomorphic phantoms using SBRT and IMRT techniques in 
homogeneous and heterogeneous media. A 9 co-planar beam IMRT plan was designed and 
delivered to a head and neck phantom for both 6MV and 10MV nominal energies. Agreement 
was assessed using the gamma technique with a passing criterion of ±3% of the maximum 
dose and ±2mm distance to agreement. The average percent of pixels passing the criterion 
was 87.2% and 90.5% for 6MV and 10MV models, respectively. The models showed a range of 
passing percentages in the sagittal and axial planes of 82.5% to 91.4% for the 6MV model and 
86.4% to 95.9% for the 10MV model. In general disagreement was limited to the edges of the 
PTV in the sagittal plane where measurement uncertainty associated with film registration was 
most likely to have an effect on the analysis due to the steep dose gradient in the region.  
     An un-modulated, 9 co-planar beam SBRT plan was delivered to the RPC’s 
anthropomorphic lung phantom. Each beam was defined by a static MLC configuration 
designed to conform the dose to the PTV. The average percent of pixels passing a ±3%/2mm 
global gamma criterion was 87.2% and 89.3% for 6MV and 10MV models, respectively. The 
range of pixels passing for the 6MV model was 84.2% to 93.9% and 85.2% to 96.5% for the 
10MV model. Similar to the head and neck benchmark results, the only consistent region of 
disagreement was along the edges of the PTV in the sagittal and coronal planes in the regions 
of the steepest dose gradient.  
     Moderately modulated, 6 co-planar beam, 6MV and 10MV IMRT plans were delivered to the 
anthropomorphic lung phantom. The addition of modulation to the heterogeneous phantom 
increased the challenge to the dose calculation tool while maintaining a clinically relevant 
setup. The average percent of pixels passing a ±3%/2mm global gamma criterion was 87.9% 
and 89.9% for 6MV and 10MV models, respectively. The range of pixels passing the ±3%/2mm 
criterion was 82.6% to 94.0% for the 6MV model and 86.0% to 94.7% for the 10MV model. 
Even with the increased difficulty of the calculation conditions, disagreement between 
measurement and calculation was minimal. 
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3.4 Conclusion 
     An analytical, multiple source model for Elekta 6MV and 10MV beams using the Dose 
Planning Method (DPM) Monte Carlo code was developed and validated within ±2% of the 
maximum dose and ±2mm distance to agreement against open field depth dose and dose 
profile measurements for field sizes ranging from 3 x 3 cm 2 to 30 x 30 cm2. On average 99.5% 
and 99.6% of the data tested for 6MV and 10MV models, respectively, met the above criterion 
using gamma analysis. 
     The first step in the commissioning process used measured percent depth dose data from a 
nominal 10 x 10 cm2 field size to determine the energy spectra and relative fluences for a 
primary point source and an extra-focal disk source through an optimization process fitting 
relative contributions of 0.25 MeV energy bins to a Fatigue-Fermi Distribution. In the same 
optimization process the relative contribution of an electron disk source was determined. 
Particle distribution was implemented directly from the literature for the extra-focal[60] and 
electron[53] sources. 
     The second step of the commissioning process matched measured and calculated dose 
profiles for an open 40 x 40 cm2 field in order to model the increase in off-axis fluence. The 
decrease in mean energy off-axis was implemented without change from Tailor et al[61]. An 
output correction was empirically applied to match the increased scatter contribution with 
increasing field size. Upon completion of the commissioning process an accurate model of 
Elekta 6MV and 10MV therapeutic x-ray beams was developed to run basic open beam dose 
calculations using the DPM Monte Carlo code. 
     The commissioned and validated multiple source models were then benchmarked against 
increasingly challenging treatment plans delivered to homogenous and heterogeneous 
anthropomorphic phantoms. The model was shown to be accurate within ±3% and ±2mm 
based on comparisons of calculated dose to enclosed thermoluminescent dosimeters (TLD) 
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and radiochromic film. Average agreement assessed using the gamma technique and a 
3%/2mm global criterion was 87.4% and 89.9% for 6MV and 10MV source models, 
respectively.   
 
  
86 
 
Chapter 4: Results and Discussion: Varian TrueBeam 6 MV and 10MV Flattening Filter 
Free Beams 
4.1 Source Model 
4.1.1 Source Model Commissioning Parameters 
     The seven optimized parameters, determined in commissioning, that describe the photon 
energy spectra, fluence contributions, and volume averaging of the ion chamber leading to an 
exaggerated penumbra for dose profiles are reported in Table 4.1 for the Varian TrueBeam 
FFF 6MV and 10MV models. The first three parameters, γ, μ, and β describe the spectrum 
shape, peak energy location, and relative scale respectively. Figure 4.1 and Figure 4.2 show a 
graphical comparison between the Varian TrueBeam FFF models and the Varian models with 
the flattening filter in place developed by Davidson et al.[35] for nominal energies of 6MV and 
10MV, respectively. 
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Parameter   
Value  
TrueBeam FFF 6MV 
Value 
 TrueBeam FFF 10MV 
Fatigue-Life distribution shape parameter, γ   9.00 12.50 
Fatigue-Life distribution location parameter, μ   0.0500 -0.0154 
Fatigue-Life distribution scale parameter, β   3.50 3.88 
Primary spectrum to extra-focal spectrum 
reduction factor   4.28 4.47 
Extra-focal fluence relative to the primary 
fluence   0.0900 0.1003 
Electron Contamination contribution (relative to 
the primary photon contribution)   0.0025 0.0015 
Standard deviation of Gaussian used to convolve 
the MC dose profile to match the measured dose 
profile during validation (in mm)   1.2 1.2 
 
Table 4.1: Optimized parameters for the source models as determined during the initial 
commissioning of the models. The first three parameters describe the shape and location of the 
spectra. The fourth through sixth parameters relate the relative contribution and energy scale of 
the three sources, and the final parameter is the standard deviation of the Gaussian kernel 
convolved with the calculated dose profiles to mimic the volume averaging effect of an ion 
chamber at the penumbra of dose profiles. 
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Figure 4.1: Comparison of commissioned TrueBeam FFF 6MV source model spectrum (red 
square) with the previously developed Varian 6MV source model (blue diamond)[35]. 
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Figure 4.2: Comparison of commissioned TrueBeam FFF 10MV source model spectrum (red 
square) with the previously developed Varian 10MV source model (blue diamond)[35]. 
 
     The extra-focal source was scaled in energy by a factor of 4.28 and 4.47 for 6MV and 10MV 
models, respectively. Their fluences, relative to the primary point source in a 10 x 10 cm2 open 
field, were found to be 9.00% and 10.03% for 6MV and 10MV models, respectively. The 
electron contamination sources, while small at 0.25% and 0.15%, respectively, were still 
included in the source model, unlike the Varian 6MV model[20, 21, 35]. For the comparison of 
the dose profiles, a Gaussian kernel of standard deviation 1.2mm was convolved with the 
calculated data to model the volume averaging effect of an ion chamber measurement. 
     The results to the second step of the commissioning process in which the off-axis fluence 
was modeled by a piecewise linear function of the cosine of the off-axis angle are shown in 
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Table 4.2. The off-axis energy correction was implemented from Georg et al.[62] without 
change.  
 
Cosine (Off-axis Angle) 
  Fluence Weight (Relative to CAX) Fluence Weight (Relative to CAX) 
  TrueBeam FFF 6MV Model TrueBeam FFF 10 MV Model 
1.00000 
 
1.0000 1.0000 
0.99970 
 
0.9597 0.9010 
0.99789 
 
0.8973 0.7852 
0.99728 
 
0.8310 0.6850 
0.99518 
 
0.7563 0.5950 
0.99250 
 
0.6939 0.5260 
0.98926 
 
0.6299 0.4609 
0.98546 
 
0.5759 0.4073 
0.98113 
 
0.5191 0.3490 
0.97630 
 
0.4600 0.1591 
0.97098 
 
0.4000 0.1167 
0.96277   0.3400 0.0700 
 
Table 4.2: Optimized coefficients to a piece-wise linear function used to describe the increase 
in off-axis fluence of TrueBeam FFF 6MV and 10MV models. Fluence weighting values are 
reported with respect to the dose measured at the central axis (CAX) for the 40 x 40 cm2 field 
size dose profile at a depth of dmax. 
 
     After completing the second step of the commissioning process, the scaling factor used to 
convert the Monte Carlo output from energy per particle to cGy per MU was determined from 
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the dose at dmax along the central axis for a 10 x 10 cm
2 field size. These values were 41.79 
and 29.49 for the 6MV and 10MV models, respectively. This factor will be applied to all 
subsequent dose calculations for the corresponding energy models. 
 
4.1.2 Fluence Map, Primary Source Size, and Machine Output Correction 
     Fluence map generation is a process that is unique to the treatment plan, patient, phantom, 
or open field delivery, and beam energy. The MLC positions for each segment weight the 
fluence by assuming 1% transmission through the leaves and an additional 1% as interleaf 
leakage. The transmission and the leakage percentages were the same for 6MV and 10MV 
models. 
     Because the source model includes a point source representing photons created within the 
target and not a finite source size, an offset of the MLC, xpen, of 0.4mm was necessary. This 
was the same offset used in the Varian model[20, 21, 35] and because the literature has 
suggested its size is nearly fixed for different nominal energies from the same 
manufacturer[69], it was left constant for both 6MV and 10MV models. 
     Unlike the previously developed Varian[35] and Elekta (Chapter 3) models, an empirically 
determined field size dependent output correction was not needed to match the calculated to 
measured dosimetry data. This is likely due to the difference in scatter contributions when 
removing the flattening filter from the linear accelerator head.  
 
4.2 Validation Testing 
4.2.1 Uncertainty 
     The uncertainty in the ion chamber measurements was estimated at 1.6% (one standard 
deviation) to match that reported in the literature[70]. The standard error of the mean in the 
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dose calculations was calculated to be no more than 1.2% using the batch method described in 
AAPM Task Group Report No. 105[22]. 
 
4.2.2 Depth Dose Data 
     The comparison between measured and calculated percent depth dose data for the 
TrueBeam FFF 6MV and 10MV models was performed for field sizes ranging from 3 x 3 cm 2 to 
40 x 40 cm2. Gamma analysis agreement using a ±2%/2mm criterion is summarized in Table 
4.3. The percentage of data passing the criterion for every field size at every depth is reported 
in the Appendix (Chapter 7). For a graphical comparison between depth dose curves of all field 
sizes please see the Appendix (Chapter 7). As representative summary the smallest (3 x 3 cm 
2), nominal (10 x 10 cm2), and largest (40 x 40 cm2) field sizes are shown for the TrueBeam 
FFF 6MV model in Figures 4.3, 4.4, and 4.5, respectively. The same field sizes are shown for 
the TrueBeam FFF 10MV model in Figure 4.6, 4.7, and 4.8, respectively. 
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Validation Results –Depth Dose Data 
Field Size (cm2) 
% Pixels Passing 
TrueBeam FFF 6MV Model TrueBeam FFF 10MV Model 
3 x 3 100.0 99.3 
4 x 4 100.0 99.3 
6 x 6 99.3 99.3 
8 x 8 100.0 100.0 
10 x 10 100.0 100.0 
20 x 20 100.0 100.0 
30 x 30 100.0 97.4 
40 x 40 100.0 96.7 
 
Table 4.3: Gamma comparison agreement for TrueBeam FFF 6MV and 10MV models using a 
±2%/2mm criterion for measured and calculated depth dose data 
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Figure 4.3: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam 
FFF 6MV beam for a 3 x 3 cm 2 field size. Gamma agreement (red circles) for each point is also 
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion. 
 
Figure 4.4: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam 
FFF 6MV beam for a 10 x 10 cm2 field size. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. 
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Figure 4.5: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam 
FFF 6MV beam for a 40 x 40 cm2 field size. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. 
 
Figure 4.6: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam 
FFF 10MV beam for a 3 x 3 cm 2 field size. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. 
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Figure 4.7: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam 
FFF 10MV beam for a 10 x 10 cm2 field size. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. 
 
Figure 4.8: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam 
FFF 10MV beam for a 40 x 40 cm2 field size. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. 
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4.2.3 Dose Profiles 
     A comparison of calculated dose profiles to measurements was performed for both 
TrueBeam FFF 6MV and FFF 10MV models at depths of dmax, 5cm, 10cm, 20cm, and 30cm for 
field sizes ranging from 3 x 3 cm 2 to 40 x 40cm2. Gamma analysis with ±2%/2mm criteria was 
used as the means of comparison and is summarized in Table 4.4. The percentages of pixels 
passing for each profile compared are reported in the Appendix (Chapter 6) along with graphs 
of each comparison. As a representative summary the smallest (3 x 3 cm 2), nominal (10 x 10 
cm2), and largest (40 x 40 cm2) field sizes are shown for the TrueBeam FFF 6MV model in 
Figures 4.9, 4.10, and 4.11, respectively. The same field sizes are shown for the FFF 10MV 
model in Figure 4.12, 4.13, and 4.14, respectively. 
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Validation Results – Dose Profile Data 
Field Size (cm2) 
% Pixels Passing 
TrueBeam FFF 6MV Model TrueBeam FFF 10MV Model 
3 x 3 99.4 98.9 
4 x 4 99.0 99.7 
6 x 6 99.6 99.6 
8 x 8 99.2 98.3 
10 x 10 98.7 96.2 
20 x 20 95.4 98.5 
30 x 30 95.3 96.1 
40 x 40 96.1 95.7 
Table 4.4: Gamma comparison agreement for TrueBeam FFF 6MV and FFF 10MV models 
using a ±2%/2mm criterion for measured and calculated dose profile data. Dose profiles were 
measured and calculated in-plane at depths of dmax (1.6cm for 6MV and 2.4cm for 10MV), 5cm, 
10cm, 20cm, and 30cm.     
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Figure 4.9: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam FFF 
6MV beam at a field size of 3 x 3 cm 2.  
 
Figure 4.10: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 6MV beam at a field size of 10 x 10 cm2.  
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Figure 4.11: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 6MV beam at a field size of 40 x 40 cm2.  
 
Figure 4.12: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 3 x 3 cm 2.  
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Figure 4.13: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 10 x 10 cm2.  
 
Figure 4.14: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 40 x 40 cm2.  
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      Agreement between calculated and measured profile data was assessed using the gamma 
technique with an evaluation criterion of ±2%/2mm. Profiles at all field sizes and depths 
showed good agreement with the minimum percentage of pixels passing being 88.0% and 
88.6% for 6MV and 10MV models respectively. The average percentage of pixels passing the 
gamma analysis was 97.8% and 97.9% for 6MV and 10MV models, respectively. Table 4.4 
displays the average agreement by field size for both 6MV and 10MV models. 
     Among the 40 profiles compared for the TrueBeam FFF 6MV model, 5 failed to achieve the 
pre-established minimum of 90% of pixels passing a ±2%/2mm gamma criterion. These failures 
occurred at field sizes of 20 x 20 cm2  at depths of 1.5cm (88.0%) and 5cm (89.0%), 30 x 30 
cm2 at depths of 1.5cm (88.1%) and 5cm (89.0%), and 40 x 40 cm2 at a depth of 1.5cm 
(89.9%). Among the profiles compared for the TrueBeam FFF 10MV model, a single profile at a 
depth of 2.4cm for a field size of 40 x 40 cm2 failed to meet the 90% requirement (88.6%). 
Failure points for both models were located in the low dose region just beyond the penumbra 
for all failing profiles. It is suspected that the model over predicts the scatter dose at these 
points just outside the field edge. Because all failing profiles were within 2% of the pre-
established criterion and occurred for larger field sizes only, it was determined that the 
disagreement would have minimal impact on the use of the calculation model for flattening filter 
free beams. One of the primary advantages of a flattening filter free beam is the increased 
dose rate achieved by removing the flattening filter and by extension reduced treatment time. 
For larger field sizes a higher degree of modulation is required to achieve desirable dose 
distributions due to the lack of flatness of the beam. This negates, and sometimes makes 
worse, the reduced treatment time achieved from the higher dose rate. It is therefore unlikely 
that a clinical plan would use field sizes at the size of the failing profiles. 
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4.3 Benchmark Testing 
4.3.1 Uncertainty 
     The measurement uncertainty in the dose distributions in the radiochromic film, normalized 
to the adjacent TLD doses, was estimated in previous studies to be between 2.6% and 3.5% at 
one standard deviation[12, 35]. By normalizing the film to the TLD dose, the uncertainty related 
to differences between the film calibration process and the actual film used in benchmarking 
was minimized. The literature details the estimated uncertainty of the TLD dose[11], the film 
uniformity, film-to-film variation, and the fit of the sensitometric curve[71]. 
     The estimated single voxel standard error of the mean in the phantom plan simulations was 
1.0% using 12 million particles per square centimeter. 
 
4.3.2 Delivery of the IMRT Head and Neck Phantom Plan: Point Dose Comparison 
     Results comparing TLD measurements to predicted doses by the multiple source model are 
shown in Table 4.5 for the TrueBeam FFF 6MV model and Table 4.6 for the TrueBeam FFF 
10MV model. TLD capsules were contained within the center of the primary PTV (four 
capsules), center of the secondary PTV (two capsules) and the center of a mock organ at risk 
(two capsules). Included in the table are average dose measurements, percent standard 
deviation from the three deliveries of each plan, a comparison of the DPM predicted dose with 
measurement expressed as a ratio of calculated dose to measured dose, and, for reference, a 
comparison of Eclipse calculated dose with measurement expressed as a ratio of calculated to 
measured dose.  
 
  
104 
 
 
 
 
TLD 
Measurement DPM Calculation Eclipse Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Pri – SP 663.7 0.2 654.4 1.0 0.986 668.0 1.4 1.006 
Pri – SA 680.8 0.2 664.8 0.7 0.976 681.9 1.7 1.002 
Pri – IP 660.5 0.6 653.6 0.6 0.990 665.9 0.0 1.008 
Pri –IA 672.2 0.6 660.4 0.8 0.983 674.0 1.9 1.003 
Pri Avg. 
    
0.984 
  
1.005 
Sec – S 571.8 0.4 568.9 0.4 0.995 577.8 2.3 1.010 
Sec – I 567.5 0.4 552.7 0.9 0.974 569.5 2.1 1.003 
Sec Avg. 
    
0.984 
  
1.007 
OAR – S 286.8 0.3 290.9 0.8 1.014 297.2 4.8 1.036 
OAR – I 295.7 0.6 299.5 1.1 1.013 302.4 0.0 1.023 
OAR Avg. 
    
1.014 
  
1.029 
 
Table 4.5: Point dose comparisons for the FFF 6MV IMRT head and neck phantom 
measurements. The measured dose is the averaged dose from the three deliveries of each 
plan. Comparison to calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio 
of calculated to measured doses. Point dose locations are indicated by Pri = Primary PTV, Sec 
= Secondary PTV, OAR = Organ at Risk, S = Superior, I = Inferior, A = Anterior, P = Posterior. 
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     For the TrueBeam FFF 6MV model the average agreement between the DPM multiple 
source model calculation and measurement in the primary PTV was 0.984. The range of 
calculated to measured dose ratios was 0.976 to 0.990. The secondary PTV showed an 
average agreement of 0.984 with a range of 0.974 to 0.995. The averaged ratio for the OAR 
TLD was 1.014 with a range of 1.013 to 1.014.  
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  TLD Measurement DPM Calculation Eclipse Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Pri – SP 658.3 0.7 670.0 0.6 1.018 662.7 1.9 1.007 
Pri – SA 662.5 0.4 671.5 0.7 1.014 666.0 0.0 1.005 
Pri – IP 660.1 0.7 676.4 0.6 1.025 665.1 0.0 1.008 
Pri –IA 658.7 0.7 672.4 0.6 1.021 665.0 0.0 1.010 
Pri Avg. 
    
1.019 
  
1.007 
Sec – S 559.7 1.3 565.6 0.4 1.010 563.3 1.1 1.006 
Sec – I 556.8 0.3 568.2 0.4 1.020 562.1 2.4 1.009 
Sec Avg. 
    
1.015 
  
1.008 
OAR – S 288.2 1.0 328.2 0.7 1.139 305.2 0.0 1.059 
OAR – I 289.7 1.1 325.2 0.0 1.123 302.4 2.9 1.044 
OAR Avg. 
    
1.131 
  
1.051 
 
Table 4.6: Point dose comparisons for the FFF 10MV IMRT head and neck phantom 
measurements. The measured dose is the averaged dose from the three deliveries of each 
plan. Comparison to calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio 
of calculated to measured doses. Point dose locations are indicated by Pri = Primary PTV, Sec 
= Secondary PTV, OAR = Organ at Risk, S = Superior, I = Inferior, A = Anterior, P = Posterior. 
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     Results for the TrueBeam FFF 10MV model show an average agreement between the DPM 
code and measurement in the primary PTV of 1.019. The range contributing to this average 
was from 1.014 to 1.025. Agreement in the secondary PTV was 1.015 with a range of 1.010 to 
1.020. Comparisons in the OAR showed an average agreement of 1.131 with a range of 1.123 
to 1.139. The poorer agreement with measurement displayed in the OAR was attributed to the 
high dose gradient in the region that was necessary to meet the plan criteria.  
      While the benchmarking of the multiple source model was based exclusively on 
measurement, comparisons to doses calculated by Eclipse are included as means of 
comparison against an actively used and state of the art treatment planning system dose 
calculation algorithm. A comparison between average agreement of DPM to measured doses 
and Eclipse to measured doses shows superior agreement for the Eclipse results in both FFF 
6MV and FFF 10MV models. The superior performance in Eclipse calculations in the PTV was 
limited to being no more than 1.1% and 1.2% better for FFF 6MV and FFF 10MV models, 
respectively. 
 
4.3.3 Delivery of the IMRT Head and Neck Phantom Plan: Dose Profile and Gamma Map 
Comparison 
     Dose profile comparison between the multiple source model and measurement are shown 
for all three major planes in Figures 4.15, 4.16, and 4.17 for the 6MV model and Figures 4.18, 
4.19, and 4.20 for the 10MV model. These comparisons are meant to be a qualitative 
assessment of the models ability to predict complex dose distributions across the volume of the 
PTV. All profiles showed good agreement between calculation and measurement. 
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Figure 4.15: A comparison of the lateral (left to right) profile from the axial film of an IMRT H&N 
delivery for the FFF 6MV model (delivery #1). 
 
 
Figure 4.16: A comparison of the AP (anterior to posterior) profile from the axial film of an 
IMRT H&N delivery for the FFF 6MV model (delivery #1). 
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Figure 4.17: A comparison of the SI (superior to inferior) profile from the axial film of an IMRT 
H&N delivery for the FFF 6MV model (delivery #1). 
 
 
Figure 4.18: A comparison of the lateral (left to right) profile from the axial film of an IMRT H&N 
delivery for the FFF 10MV model (delivery #1). 
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Figure 4.19: A comparison of the AP (anterior to posterior) profile from the axial film of an 
IMRT H&N delivery for the FFF 10MV model (delivery #1). 
 
Figure 4.20: A comparison of the SI (superior to inferior) profile from the axial film of an IMRT 
H&N delivery for the FFF 10MV model (delivery #1). 
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     To evaluate the models performance at describing the penumbra, MLC leakage, rounded 
leaf tips, and leaf transmission in highly modulated fields, gamma analysis was performed 
using a ±3%/2mm criterion. The analysis considers dose differences as relative percentage 
and the distance to agreement to assess overall agreement and identify locations of difficulty to 
the model. The resulting gamma maps from a single irradiation in the axial and sagittal plans 
are shown in Figure 4.21 and Figure 4.22 for the 6MV model and Figure 4.23 and Figure 4.24 
for the 10MV model. Gamma maps for all three deliveries of each nominal energy are included 
in the Appendix. For the IMRT head and neck plan, the average percent of pixels passing for 
the 6MV comparison was 90.1% with a range of 80.3% to 95.9%. The 10MV comparison 
averaged 87.2% of pixels passing the ±3%/2mm criterion with a range of 75.5% to 93.1%. 
Table 4.7 reports the average agreement in the sagittal and axial planes for both the 6MV and 
10MV models. 
 
 
TrueBeam FFF 6MV TrueBeam FFF 10MV 
  Axial Sagittal Axial Sagittal 
Delivery #1 93.6 94.3 87.9 90.5 
Delivery #2 89.4 86.6 93.1 85.9 
Delivery #3 80.3 95.9 75.5 90.1 
Average 87.8 92.3 85.5 88.8 
 
Table 4.7: Percentage of pixels passing a ±3%/2mm gamma criterion for IMRT head and neck 
plans for both TrueBeam FFF 6MV and 10MV models. Agreement was evaluated in both the 
axial and sagittal planes for three deliveries of each plan. 
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Figure 4.21: IMRT head and neck delivery comparison for the axial plane of delivery #1 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
93.6% of pixels passed.  
 
Figure 4.22: IMRT head and neck delivery comparison for the sagittal plane of delivery #1 for 
the TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 94.3% of pixels passed.  
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Figure 4.23: IMRT head and neck delivery comparison for the axial plane of delivery #1 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 87.9% of pixels passed.  
 
Figure 4.24: IMRT head and neck delivery comparison for the sagittal plane of delivery #1 for 
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 90.5% of pixels passed.  
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     Qualitative evaluation of the axial gamma maps suggested that the model was challenged 
most near the OAR where the dose gradient would be steepest. Failure regions of the sagittal 
gamma maps were consistent with the axial gamma maps in suggesting that the model was 
challenged most posterior to the PTV in the region near the OAR. Even with the increased 
challenge near the steep dose gradient, passing rates were above the pre-established 
threshold of 85%. 
 
4.3.4 Delivery of the SBRT Thorax Phantom Plan: Point Dose Comparison 
     The results to point dose comparisons between the developed model and TLD 
measurements in the anthropomorphic thorax phantom are shown in Table 4.8 and Table 4.9. 
Double packed TLD were contained in the center of the target (two), in the heart (one), and in 
the spinal cord (one). The table includes average dose measurements, percent standard 
deviation from the three deliveries of each plan, a comparison of the DPM predicted dose with 
measurement expressed as a ratio of calculated dose to measured dose, and, for reference, a 
comparison of Eclipse calculated doses with measurement expressed as a ratio of measured to 
calculated dose. 
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TLD 
Measurement DPM Calculation Eclipse Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
PTV – S 788.2 0.4 796.7 0.5 1.011 812.9 0.0 1.031 
PTV – I 783.0 0.1 786.3 0.4 1.004 803.1 0.5 1.026 
PTV Avg. 
    
1.007 
  
1.028 
OAR – Heart 170.6 0.4 177.5 1.7 1.040 168.8 0.0 0.989 
OAR – Cord 155.2 0.0 177.5 2.6 1.144 179.4 2.6 1.156 
 
Table 4.8: Point dose comparisons for the FFF 6MV SBRT lung phantom measurements. The 
measured dose is the averaged dose from the three deliveries of each plan. Comparison to 
calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio of calculated to 
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR = 
Organ at Risk, S = Superior, I = Inferior. 
 
     For the TrueBeam FFF 6MV model the average agreement between the DPM multiple 
source model calculation and measurement in the PTV was 1.007. The range of calculated to 
measured dose ratios was 1.004 to 1.011. The ratio for the heart TLD was 1.040, and the ratio 
for the cord TLD was 1.144.  
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  TLD Measurement DPM Calculation Eclipse Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
PTV – S 819.6 0.6 828.3 0.6 1.011 836.6 0.6 1.021 
PTV – I 813.9 0.4 810.0 2.1 0.995 821.3 0.6 1.009 
PTV Avg. 
    
1.003 
  
1.015 
OAR – Heart 155.5 0.7 152.0 2.6 0.978 155.0 0.0 0.997 
OAR – Cord 150.5 0.5 170.0 0.0 1.130 169.9 0.0 1.129 
 
Table 4.9: Point dose comparisons for the FFF 10MV SBRT lung phantom measurements. The 
measured dose is the averaged dose from the three deliveries of each plan. Comparison to 
calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio of calculated to 
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR = 
Organ at Risk, S = Superior, I = Inferior. 
 
     The average agreement between the DPM model and the PTV for the TrueBeam FFF 10MV 
model was 1.003. The range of the values for the PTV agreement was 0.995 to 1.011. The 
calculated to measured ratios for the heart and cord TLDs were 0.978 and 1.130, respectively. 
     It is important to note that while the OAR calculated doses showed poorer agreement with 
measurements for 6MV and 10MV models, the uncertainty in the measured dose is unknown at 
such low doses. The standards used for low dose measurements are done at doses of 8Gy 
and 3Gy, nearly 3 times the dose of both the heart and cord measurement for the lower of the 
two standard doses. At doses near 1Gy, as seen in both of the OAR TLD, the RPC does not 
have data documenting the accuracy of their TLD measurement process for phantom 
irradiations. 
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     Even though the benchmarking of the multiple source model was based exclusively on 
measurement, comparisons to doses calculated by Eclipse are included as means of 
comparison against an actively used and state of the art treatment planning system dose 
calculation algorithm. A direct comparison between the DPM calculated doses and the Eclipse 
calculated doses show the DPM calculation to agree better with measurement results in the 
PTVs and comparably within the OARs. 
 
4.3.5 Delivery of the SBRT Thorax Phantom Plan: Dose Profile and Gamma Map 
Comparison 
     Dose profile comparison between the multiple source model and measurement are shown 
for all three major planes in Figures 4.25, 4.26, 4.27 for the FFF 6MV model and Figures 4.28, 
4.29, and 4.30 for the FFF 10MV model. These comparisons are meant to be a qualitative 
assessment of the models ability to predict complex dose distributions across the volume of the 
PTV. All profiles showed good agreement between calculation and measurement. 
 
Figure 4.25: A comparison of the lateral (left to right) profile from the axial film of an SBRT lung 
delivery for the FFF 6MV model (delivery #1). 
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Figure 4.26: A comparison of the AP (anterior to posterior) profile from the axial film of an 
SBRT lung delivery for the FFF 6MV model (delivery #1). 
 
 
Figure 4.27: A comparison of the SI (superior to inferior) profile from the sagittal film of an 
SBRT lung delivery for the FFF 6MV model (delivery #1). 
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Figure 4.28: A comparison of the lateral (left to right) profile from the axial film of an SBRT lung 
delivery for the FFF 10MV model (delivery #1). 
 
 
Figure 4.29: A comparison of the AP (anterior to posterior) profile from the axial film of an 
SBRT lung delivery for the FFF 10MV model (delivery #1). 
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Figure 4.30: A comparison of the SI (superior to inferior) profile from the sagittal film of an 
SBRT lung delivery for the FFF 10MV model (delivery #1). 
 
     The models ability to describe the beam penumbra, MLC leakage, rounded leaf tips, and 
leaf transmission in unmodulated fields in a heterogeneous medium provided by the lung 
phantom was evaluated using the gamma technique with a ±3%/2mm criterion. The analysis 
considers the dose differences as a percentage of the maximum dose and distance to 
agreement to assess overall agreement between dose distributions calculated by the multiple 
source model and measured by the radiochromic film in the phantom. In this way resulting 
gamma maps can be used to identify areas where the model may be deficient while allowing 
for positional measurement uncertainty to be accounted for in the distance to agreement 
criterion.  
     The gamma maps for a single irradiation and comparison to source model calculation for the 
6MV model are showing in Figures 4.31, 4.32, and 4.33 for the axial, sagittal, and coronal 
planes, respectively. Gamma maps for each delivery are included in the Appendix. The 
average agreement, expressed as a percentage of pixels passing the gamma criterion, were 
87.8%, 90.4%, and 94.2% for axial, sagittal, and coronal planes, respectively. Agreement for 
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the axial plane ranged from 84.5% to 91.5%. Agreement for the sagittal plane ranged from 
85.5% to 95.2%, and the range of agreement for the coronal plane was 85.5% to 98.7%.  
 
 
Figure 4.31: Lung SBRT delivery comparison for the axial plane of delivery #1 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
91.5% of pixels passed.  
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Figure 4.32: Lung SBRT delivery comparison for the sagittal plane of delivery #1 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
85.5% of pixels passed.  
 
Figure 4.33: Lung SBRT delivery comparison for the coronal plane of delivery #1 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
98.7% of pixels passed. 
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     The gamma maps corresponding to the comparison of a single irradiation to the calculated 
dose of the 10MV source model are showing in Figures 4.34, 4.35, and 4.36 for axial, sagittal, 
and coronal planes, respectively. Gamma maps from all other deliveries are included in the 
Appendix for reference. The average agreement was 91.5%, 89.5%, and 94.2% for axial, 
sagittal, and coronal planes, respectively. The range of values for the axial plane was 87.4% to 
95.8%, for the sagittal plane 88.1% to 91.4%, and for the coronal plane 91.9% to 98.1%. 
 
 
Figure 4.34: Lung SBRT delivery comparison for the axial plane of delivery #1 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 91.4% of pixels passed. 
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Figure 4.35: Lung SBRT delivery comparison for the sagittal plane of delivery #1 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 88.9% of pixels passed.  
 
Figure 4.36: Lung SBRT delivery comparison for the coronal plane of delivery #1 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 91.9% of pixels passed. 
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     The passing rate of comparisons for each plane for all three deliveries with respect to the 
DPM source model calculation is shown for both 6MV and 10MV models in Table 4.10.  
  TrueBeam FFF 6MV TrueBeam FFF 10MV 
  Axial Sagittal Coronal Axial Sagittal Coronal 
Delivery #1 91.5 85.5 98.7 91.4 88.9 91.9 
Delivery #2 84.5 90.3 98.4 87.4 88.1 92.7 
Delivery #3 87.5 95.2 85.5 95.8 91.4 98.1 
Average 87.8 90.4 94.2 90.2 88.3 89.5 
 
Table 4.10: Percentage of pixels passing a ±3%/2mm gamma criterion for SBRT lung plans for 
both TrueBeam FFF 6MV and FFF 10MV models. Agreement was evaluated in the axial, 
sagittal, and coronal planes for three deliveries of each plan. 
 
     A qualitative evaluation of the gamma maps showed no consistent failure regions in the 
comparison in the axial plane. The agreement in the sagittal and coronal planes appeared to be 
challenged most at the edges of the PTV. This is largely attributed to the sensitivity of the 
comparison to the registration of film to the phantom. Because both film plane comparisons 
consist of two pieces of film that need to be aligned during scanning, the registration 
uncertainty is higher than for the axial plane which consists of single piece of film. Furthermore 
the high dose gradients at the edges of the PTV make the analysis more sensitive to a small 
translational shift either in the film registration or phantom setup. Even with the increased 
registration uncertainty, passing rates were above the pre-established threshold of 85%. 
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4.3.6 Delivery of the IMRT Thorax Phantom Plan: Point Dose Comparison 
     The results to point dose comparisons between the developed model and TLD 
measurements in the anthropomorphic thorax phantom are shown in Table 4.11 and Table 
4.12. Double packed TLD were contained in the center of the target (two), in the heart (one), 
and in the spinal cord (one). The table includes dose measurements, a comparison of the DPM 
predicted dose with measurement expressed as a ratio of calculated dose to measured dose, 
and, for reference, a comparison of Eclipse calculated doses with measurement expressed as 
a ratio of calculated to measured dose. 
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TLD 
Measurement DPM Calculation Eclipse Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
PTV – S 625.4 0.5 616.7 0.8 0.986 636.0 0.7 1.017 
PTV – I 625.1 1.0 630.0 1.2 1.008 644.1 0.0 1.030 
PTV Avg. 
    
0.997 
  
1.024 
OAR – Heart 62.5 1.0 58.0 8.4 0.927 60.0 8.3 0.959 
OAR – Cord 47.5 0.4 50.0 0.0 1.054 57.8 0.0 1.218 
 
Table 4.11: Point dose comparisons for the FFF 6MV IMRT lung phantom measurements. The 
measured dose is the averaged dose from the three deliveries of each plan. Comparison to 
calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio of calculated to 
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR = 
Organ at Risk, S = Superior, I = Inferior. 
 
     For the TrueBeam FFF 6MV model the average agreement between the DPM multiple 
source model calculation and measurement in the PTV was 0.997. The range of calculated to 
measured dose ratios was 0.986 to 1.008. The ratio for the heart TLD was 0.927, and the ratio 
for the cord TLD was 1.054.  
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  TLD Measurement DPM Calculation Eclipse Calculation 
Point Dose 
Location 
Avg. 
(cGy) 
% Std. 
Dev. 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
Avg. 
(cGy) 
% Std. 
Dev. 
Ratio 
Calc/Meas 
PTV – S 624.2 0.5 630.0 0.0 1.009 631.0 0.0 1.011 
PTV – I 643.4 0.5 630.0 0.0 0.979 626.9 0.0 0.974 
PTV Avg. 
    
0.994 
  
0.993 
OAR – Heart 62.4 1.3 68.0 0.0 1.090 61.5 8.0 0.985 
OAR – Cord 52.5 0.8 50.0 0.0 0.953 51.0 0.0 0.972 
 
Table 4.12: Point dose comparisons for the FFF 10MV IMRT lung phantom measurements. 
The measured dose is the averaged dose from the three deliveries of each plan. Comparison 
to calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio of calculated to 
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR = 
Organ at Risk, S = Superior, I = Inferior. 
 
     The average agreement between the DPM model and the PTV for the TrueBeam FFF 10MV 
model was 0.994. The range of the values for the PTV agreement was 0.979 to 1.009. The 
calculated to measured ratio for the heart and cord TLDs were 1.090 and 0.953, respectively. 
     It is important to note that while the OAR calculated doses showed poorer agreement with 
measurements for 6MV and 10MV models, the uncertainty in the measured dose is unknown at 
such low doses. The standards used for low dose measurements are done at doses of 8Gy 
and 3Gy, nearly 3 times the dose of both the heart and cord measurement for the lower of the 
two standard doses. At doses near 1Gy, as seen in both of the OAR TLD, the RPC does not 
have data documenting the accuracy of their TLD measurement process for phantom 
irradiations. 
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     Even though the benchmarking of the multiple source model was based exclusively on 
measurement, comparisons to doses calculated by Eclipse are included as means of 
comparison against an actively used and state of the art treatment planning system dose 
calculation algorithm. A direct comparison between the DPM calculated dose performance to 
the Eclipse calculated dose performance shows comparable results in the PTV TLD capsules 
and inferior performance within the OARs. 
 
4.3.7 Delivery of the IMRT Thorax Phantom Plan: Dose Profile and Gamma Map 
Comparison 
     Dose profile comparison between the multiple source model and measurement are shown 
for all three major planes in Figures 4.37, 4.38, 4.39 for the 6MV model and Figures 4.40, 4.41, 
and 4.42 for the 10MV model. These comparisons are meant to be a qualitative assessment of 
the models ability to predict complex dose distributions across the volume of the PTV. All 
profiles showed good agreement between calculation and measurement. 
 
Figure 4.37: A comparison of the lateral (left to right) profile from the axial film of an IMRT lung 
delivery for the FFF 6MV model (delivery #1). 
 
130 
 
 
 
Figure 4.38: A comparison of the AP (anterior to posterior) profile from the axial film of an 
IMRT lung delivery for the FFF 6MV model (delivery #1). 
 
 
Figure 4.39: A comparison of the SI (superior to inferior) profile from the sagittal film of an 
IMRT lung delivery for the FFF 6MV model (delivery #1). 
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Figure 4.40: A comparison of the lateral (left to right) profile from the axial film of an IMRT lung 
delivery for the FFF 10MV model (delivery #1). 
 
 
Figure 4.41: A comparison of the AP (anterior to posterior) profile from the axial film of an 
IMRT lung delivery for the FFF 10MV model (delivery #1). 
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Figure 4.42: A comparison of the SI (superior to inferior) profile from the sagittal film of an 
IMRT lung delivery for the FFF 10MV model (delivery #1). 
 
     The models ability to describe the beam penumbra, MLC leakage, rounded leaf tips, and 
leaf transmission in unmodulated fields in a heterogeneous medium provided by the lung 
phantom was evaluated using the gamma technique with a ±3%/2mm criterion. The analysis 
considers the dose differences as a percentage of the maximum dose and distance to 
agreement to assess overall agreement between dose distributions calculated by the multiple 
source model and measured by the radiochromic film in the phantom. In this way resulting 
gamma maps can be used to identify areas where the model may be deficient while allowing 
for positional measurement uncertainty to be accounted for in the distance to agreement 
criterion.  
     The gamma maps for a single irradiation and comparison to source model calculation for the 
FFF 6MV model are showing in Figures 4.43, 4.44, and 4.45 for the axial, sagittal, and coronal 
planes respectively. Gamma maps for each delivery are included in the Appendix. The average 
agreement, expressed as a percentage of pixels passing the gamma criterion, were 92.0%, 
91.2%, and 91.5% for axial, sagittal, and coronal planes, respectively. Agreement for the axial 
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plane ranged from 91.0% to 93.5%. Agreement for the sagittal plane ranged from 87.4% to 
94.3%, and the range of agreement for the coronal plane was 88.4% to 93.9%.  
 
 
Figure 4.43: Lung IMRT delivery comparison for the axial plane of delivery #1 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
91.0% of pixels passed.  
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Figure 4.44: Lung IMRT delivery comparison for the sagittal plane of delivery #1 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
91.8% of pixels passed.  
 
Figure 4.45: Lung IMRT delivery comparison for the coronal plane of delivery #1 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
93.9% of pixels passed. 
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     The gamma maps corresponding to the comparison of a single irradiation to the calculated 
dose of the FFF 10MV source model are showing in Figures 4.46, 4.47, and 4.48 for axial, 
sagittal, and coronal planes, respectively. Gamma maps from all other deliveries are included 
in the Appendix for reference. The average agreement was 95.3%, 89.9%, and 95.0% for axial, 
sagittal, and coronal planes, respectively. The range of values for the axial plane was 93.0% to 
97.4%, for the sagittal plane 85.2% to 93.6%, and for the coronal plane 92.1% to 96.6%. 
 
 
Figure 4.46: Lung IMRT delivery comparison for the axial plane of delivery #3 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 92.3% of pixels passed. 
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Figure 4.47: Lung IMRT delivery comparison for the sagittal plane of delivery #3 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 90.8% of pixels passed.  
 
Figure 4.48: Lung IMRT delivery comparison for the coronal plane of delivery #3 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 96.6% of pixels passed. 
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     The passing rate of comparisons for each plane for all three deliveries with respect to the 
DPM source model calculation is shown for both FFF 6MV and FFF 10MV models in Table 
4.13.  
  TrueBeam FFF 6MV TrueBeam FFF 10MV 
  Axial Sagittal Coronal Axial Sagittal Coronal 
Delivery #1 91.0 91.8 93.9 95.6 85.2 92.1 
Delivery #2 91.4 87.4 88.4 97.4 93.6 96.4 
Delivery #3 93.5 94.3 92.4 93.0 90.8 96.6 
Average 92.0 90.4 91.5 95.3 89.9 95.0 
 
Table 4.13: Percentage of pixels passing a ±3%/2mm gamma criterion for IMRT lung plans for 
both TrueBeam FFF 6MV and 10MV models. Agreement was evaluated in the axial, sagittal, 
and coronal planes for three deliveries of each plan. 
 
     A qualitative evaluation of the gamma maps showed the model was challenged most along 
the edges of the beam profile outside of the PTV region. This region is more sensitive to the 
rotational positioning of the film during scanning because of the combination of the steeper 
dose gradient and the increased distance from the axis of rotation at the center of the film. The 
agreement in the sagittal and coronal planes appeared to be challenged most at the edges of 
the PTV. This is largely attributed to the sensitivity of the comparison to the registration of film 
to the phantom. Additionally, the film measurement for the FFF 6MV comparisons yielded 
doses lower than 1Gy at the corners of the axial films. At doses in this region the sensitometric 
curve used results in lower accuracy of the measured dose. Because both film plane 
comparisons consist of two pieces of film that need to be aligned during scanning, the 
registration uncertainty is higher than for the axial plane which consists of single piece of film. 
138 
 
Furthermore the high dose gradients at the edges of the PTV make the analysis more sensitive 
to a small translational shift either in the film registration or phantom setup. Even with the 
increased registration and position uncertainty, passing rates were above the pre-established 
threshold of 85%. 
 
4.3.8 Benchmark Summary 
     The average and range of the percent of pixels passing a ±3%/2mm global gamma criterion 
for each phantom for both TrueBeam FFF 6MV and FFF 10MV source models is presented in 
Table 4.14.  
 
    IMRT H&N SBRT Lung IMRT Lung 
TrueBeam 
FFF 6MV 
Average 90.0 90.8 89.6 
Range 80.3 – 95.9 84.5 – 98.4 85.1 – 97.5 
TrueBeam 
FFF 10MV 
Average 87.2 91.7 93.4 
Range 75.5 – 93.1 87.4 – 98.1 85.2 – 97.4 
 
Table 4.14: The average and range of the percent of pixels passing a ±3%/2mm gamma 
criterion for TrueBeam FFF 6MV and FFF 10MV source models as assessed through three 
repeated deliveries for three different treatment plans to anthropomorphic phantoms.  
 
     Each multiple source model was benchmarked against three progressively challenging 
treatment plans delivered to anthropomorphic phantoms using SBRT and IMRT techniques in 
homogeneous and heterogeneous media. A 9 co-planar beam IMRT plan was designed and 
delivered to a head and neck phantom for both FFF 6MV and FFF 10MV nominal energies. 
Agreement was assessed using the gamma technique with a passing criterion of ±3% of the 
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maximum dose and ±2mm distance to agreement. The average percent of pixels passing the 
criterion was 90.0% and 87.2% for FFF 6MV and FFF 10MV models, respectively. The models 
showed a range of passing percentages in the sagittal and axial planes of 80.3% to 95.9% for 
the FFF 6MV model and 75.5% to 93.1% for the FFF 10MV model. In general disagreement 
was limited to regions near the organ at risk where the dose gradient was greatest.  
     An un-modulated, 9 co-planar beam SBRT plan was delivered to the RPC’s 
anthropomorphic lung phantom. Each beam was defined by a static MLC configuration 
designed to conform the dose to the PTV. The average percent of pixels passing a ±3%/2mm 
global gamma criterion was 90.8% and 91.7% for 6MV and 10MV models, respectively. The 
range of pixels passing for the FFF 6MV model was 84.5% to 98.4% and 87.4% to 98.1% for 
the FFF 10MV model. 
     Moderately modulated, 6 co-planar beam, FFF 6MV and FFF 10MV IMRT plans were 
delivered to the anthropomorphic lung phantom. The addition of modulation to the 
heterogeneous phantom increased the challenge to the dose calculation tool while maintaining 
a clinically relevant setup. The average percent of pixels passing a ±3%/2mm global gamma 
criterion was 89.6% and 93.4% for FFF 6MV and FFF 10MV models, respectively. The range of 
pixels passing the criterion was 85.1% to 97.5% for the FFF 6MV model and 85.2% to 97.4% 
for the FFF 10MV model. Even with the increased difficulty of the calculation conditions, 
disagreement between measurement and calculation was minimal. 
 
4.4 Conclusion 
     An analytical, multiple source model for TrueBeam FFF 6MV and FFF 10MV beams using 
the Dose Planning Method (DPM) Monte Carlo code was developed and validated within ±2% 
of the maximum dose and ±2mm distance to agreement against open field depth dose and 
dose profile measurements for field sizes ranging from 3 x 3 cm 2 to 40 x 40 cm2. On average 
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98.1% of the data tested for both 6MV and 10MV models met the above criterion using gamma 
analysis. 
     The first step in the commissioning process used measured percent depth dose data from a 
nominal 10 x 10 cm2 field size to determine the energy spectra and relative fluences for a 
primary point source and an extra-focal disk source through an optimization process fitting 
relative contributions of 0.25 MeV energy bins to a Fatigue-Fermi Distribution. In the same 
optimization process the relative contribution of an electron disk source was determined. 
Particle distribution was implemented directly from the literature for the extra-focal[60] and 
electron[53] sources. 
     The second step of the commissioning process matched measured and calculated dose 
profiles for an open 40 x 40 cm2 field in order to model the increase in off-axis fluence. The 
decrease in mean energy off-axis was implemented without change from Georg et al[62]. Upon 
completion of the commissioning process an accurate model of TrueBeam FFF 6MV and FFF 
10MV therapeutic x-ray beams was developed to run basic open beam dose calculations using 
the DPM Monte Carlo code. 
     The commissioned and validated multiple source models were then benchmarked against 
increasingly challenging treatment plans delivered to homogenous and heterogeneous 
anthropomorphic phantoms. The model was shown to be accurate within ±3% and ±2mm 
based on comparisons of calculated dose to enclosed thermoluminescent dosimeters (TLD) 
and radiochromic film. Average agreement assessed using the gamma technique and a 
±3%/2mm global criterion was 90.1% and 90.8% for FFF 6MV and FFF 10MV source models, 
respectively. 
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Chapter 5: Robustness Study at Outside Institutions: Elekta and Varian TrueBeam FFF 
6MV and 10MV 
5.1 Introduction 
     The Radiological Physics Center (RPC) has published the results for its anthropomorphic 
phantom audit program showing varying degrees of success amongst institutions[13, 17]. 
There is reason to believe that one potential source of discrepancy between these 
measurement to calculated dose comparisons is the accuracy of the dose calculations 
algorithms in heterogeneous media[12, 18].  Previously, the RPC has been unable to verify the 
accuracy of this step in the radiation therapy treatment process[19]. In order to ensure a higher 
degree of consistency among institutions participating in National Cancer Institute (NCI) funded 
clinical trials and improve upon patient safety, the RPC began the development of an 
independent dose calculation tool to be used in the auditing process[20, 21, 35].  
     In its current state, the dose calculation tool includes models of Varian 6MV and 10MV 
therapeutic linear accelerators. Chapters 3 and 4 detailed the inclusion of Elekta 6MV and 
10MV models and Varian TrueBeam FFF 6MV and FFF 10MV models, respectively. The 
addition of these four models were intended to cover the majority of the approximately 25% of 
monitored beams not modeled by the dose calculation tool. In order to be truly useful as an 
auditing tool, the models must be able to accurately predict dose distributions for all linear 
accelerators of a common manufacturer and not just the linear accelerator whose dosimetry 
data was used during commissioning of the models. RPC collected dosimetry data suggests 
that this is possible as over 90% of all beams from a common manufacturer have shown 
agreement within ±2%[55].  
 
5.2 Materials and Methods 
     The RPC conducts their phantom audits through a comparison of TLD measurement and 
film measurement to institution submitted calculated dosimetry data. The measurement data 
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from the phantom irradiation along with the institution submitted treatment plan data and 
calculated doses are archived with the auditing report sent to the institution. While it is not 
required for the audit, if the treatment plan data contains the plan information contained within 
the DICOM RT plan (RP) file, this archived plan file can be used as input to the Monte Carlo 
models described in Chapters 2-4. This provides all the necessary information to run a 
comparison between Monte Carlo calculated doses and phantom measurements similar to the 
model benchmarking performed in Chapter 3 Section 3 and Chapter 4 Section 3.  
     To evaluate the models performance against measurements on beams not used in the 
commissioning of the model, a comparison between Monte Carlo calculated dose and 
measurement dose from past phantom audits will be performed. Audits chosen for the 
comparison will be selected based on three criteria.  
     First, the phantom audit must have passed the RPC’s criteria. For the IMRT head and neck 
phantom this requires TLD measurements to be within ±7% of the predicted calculated dose 
and gamma agreement to be >85% at a ±7%/4mm criterion. For the lung phantom the TLD 
measurements must be within ±5% of a measured to calculated dose ratio of 0.97 for 
deterministic dose calculation algorithms and ±5% of a ratio of 1.00 for Monte Carlo dose 
calculation algorithms. An analysis of past audits on the lung phantom has shown a systematic 
disagreement between measurement and deterministic calculations of 3-4%[72]. By requiring 
the measurement to be within ±5% of a ratio of 0.97 the systematic offset is accounted for in 
comparisons to doses calculated by deterministic algorithms. Additionally, the gamma analysis 
of the film measurement compared to dose calculation must be in agreement for >85% of data 
tested with a ±5%/5mm criterion. 
     The RPC’s phantoms act as an end to end test of the treatment process. The AAPM Task 
Group Report Number 85 breaks down the acceptable uncertainties of the entire treatment 
process, of which the dose calculations are a small part[73]. For this reason, the past phantom 
audits to be compared to the tool must show agreement between measurement and calculated 
data superior to the minimum requirements for passing the audit. Preference will be given to 
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audits with TLD measurements within ±3% of the predicted calculated dose. For the lung 
phantom audits, the ±3% acceptance criteria will be centered on a measured to calculated 
dose ratio of 0.97 for doses calculated by deterministic algorithms. To minimize the impact of 
measurement uncertainty caused by collecting data from phantoms irradiated by outside 
institutions, comparisons will be restricted to the TLD contained in the PTV for both phantoms. 
     The final assessment for selection of the phantom audit will be based on a comparison of 
the dose profile agreement included in the institution’s audit report. This will be a subjective 
evaluation of the dose distribution shape and phantom alignment. While offsets within ±3mm in 
the phantom positioning can be accounted for in the registration of the calculated dose to the 
film measurements, accounting for larger offsets would increase the uncertainty in the 
comparison to unacceptable levels. While some offsets can be accounted for, a delivery error 
resulting in a different dose distribution cannot be accurately predicted to input into the multiple 
source model calculation. While this change may not affect the passing rate using a ±7%/4mm 
or ±5%/5mm gamma criterion in the phantom audit, it will likely cause failure at the more 
restrictive ±3%/2mm criterion that has been used on the benchmarking studies of the model. 
     Table 5.1 and Table 5.2 report the phantom audits chosen for the comparison of multiple 
source model calculations to past measurements for head and neck phantoms and lung 
phantoms, respectively. Because FFF is relatively new delivery technique and 10MV beams 
are less common than 6MV beams, there were no TrueBeam FFF 10MV phantom audits. 
Likewise, only the lung phantom has been used for auditing TrueBeam FFF 6MV beams. The 
use of Elekta 10MV beams is also uncommon among RPC audited institutions. There were no 
Elekta 10MV phantom audits that met the selection criteria. 
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Delivery Manufacturer Model 
Energy 
(MV) 
Technique TPS 
H&N Plan 
#1 
Elekta Synergy 6MV SMLC Pinnacle 
H&N Plan 
#2 
Elekta Agility S 6MV SMLC Pinnacle 
 
Table 5.1: Summary of head and neck phantom audits chosen for a measurement based 
comparison to Monte Carlo recalculation of plan dose. Both plans were step and shoot IMRT, 
or static MLC (SMLC), deliveries. 
 
Delivery Manufacturer Model 
Energy 
(MV) 
Technique TPS 
Lung Plan 
#1 
Varian TrueBeam 6MV FFF 3D Pinnacle 
Lung Plan 
#2 
Varian TrueBeam 6MV FFF 3D Pinnacle 
Lung Plan 
#3 
Elekta Synergy 6MV SMLC Pinnacle 
 
Table 5.2: Summary of lung phantom audits chosen for a measurement based comparison to 
Monte Carlo recalculation of plan dose. Delivery techniques were either 3D or static MLC 
(SMLC). 
 
5.3 Results 
5.3.1 Point Dose Comparison 
     The results to the point dose comparisons for the past audit study are reported in Table 5.3 
for head and neck phantom audits. The recalculation of doses for the head and neck audits 
resulted in an average calculated to measured TLD dose ratio in the PTV of 1.019. The 
institution reported TLD doses as determined by the TPS yielded an average agreement of 
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1.020 in the PTV. The mean agreement of the two calculated doses was not significant 
according to a paired t-test (p=0.9293). The range of agreement in the PTV for the multiple 
source model recalculated doses was 1.005 to 1.030. The corresponding range for TPS 
agreement was 0.991 to 1.050.  
 
Delivery 
PTV TLD SA PTV TLD IA PTV TLD SP PTV TLD IP PTV TLD Avg. 
TPS DPM TPS DPM TPS DPM TPS DPM TPS DPM 
H&N Plan 
#1 
1.003 1.005 1.015 1.027 0.991 1.019 1.010 1.027 1.005 1.020 
H&N Plan 
#2 
1.040 1.015 1.050 1.028 1.019 1.003 1.031 1.030 1.035 1.019 
 
Table 5.3: Point dose comparisons for the multiple source model recalculation of the head and 
neck phantom audits. Comparison to calculated doses by DPM and the institution reported 
doses calculated by the TPS are expressed as a ratio of calculated to measured doses. Point 
dose locations were restricted to within the PTV. S = Superior, I = Inferior, A = Anterior, P = 
Posterior. 
 
     The results to the point dose comparisons for the past lung phantom audit study is reported 
in Table 5.4. The averaged ratio of DPM recalculated dose to measurement was 0.986 
compared to 1.023 for institution submitted doses calculated by the TPS. The mean agreement 
was determined to be significant using a paired t-test (p=0.0004). Using the same statistical 
analysis, the difference from 1.000 was not shown to be significantly better for the DPM 
recalculated doses with respect to the TPS calculated doses (p=0.3276). The range of the 
agreement for recalculated doses was 0.975 to 0.995. The range of the ratio of TPS calculated 
doses to measurement was 1.007 to 1.042. 
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Delivery 
PTV TLD S PTV TLD I PTV TLD Avg. 
TPS DPM TPS DPM TPS DPM 
Lung Plan #1 1.021 0.994 1.013 0.989 1.017 0.991 
Lung Plan #2 1.007 0.975 1.015 0.978 1.011 0.977 
Lung Plan #3 1.038 0.988 1.042 0.995 1.040 0.992 
 
Table 5.4: Point dose comparisons for the multiple source model recalculation of the lung 
phantom audits. Comparison to calculated doses by DPM and the institution reported doses 
calculated by the TPS are expressed as a ratio of calculated to measured doses. Point dose 
locations were restricted to within the PTV. S = Superior, I = Inferior. 
 
5.3.2 Gamma Map Comparison 
     To compare the multiple source models’ accuracy in modeling the beam penumbra, MLC 
leaf tips, MLC transmission, and MLC leakage for outside institution beams, agreement 
between DPM recalculated doses and archived film measurements were evaluated using the 
gamma technique[68]. The analysis considers dose differences as relative percentage and the 
distance to agreement to assess overall agreement and identify locations of difficulty to the 
model. The analysis was performed with ±3%/2mm and ±5%/3mm criteria. All film 
measurements were also compared to the TPS calculated dose submitted by the audited 
institution using the same technique and criteria. The results of the comparisons are reported in 
Table 5.5 and Table 5.6 for head and neck audits using ±3%/2mm and ±5%/3mm criteria, 
respectively. Table 5.7 and Table 5.8 report the agreement for the lung audits using ±3%/2mm 
and ±5%/3mm criteria, respectively. The corresponding gamma maps for each comparison at 
each criterion are presented in the Appendix (Chapter 7). 
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Delivery 
DPM TPS 
Axial Sagittal Axial Sagittal 
H&N Plan 
#1 
59.1 69.4 67.6 75.3 
H&N Plan 
#2 
88.4 52.5 85.9 69.8 
 
Table 5.5: Percentages of pixels passing a ±3%/2mm gamma criterion for previous head and 
neck audits are reported. Agreement was evaluated in the axial and sagittal planes. 
 
Delivery 
DPM TPS 
Axial Sagittal Axial Sagittal 
H&N Plan 
#1 
82.1 88.2 88.6 98.9 
H&N Plan 
#2 
98.3 76.8 98.4 86.3 
 
Table 5.6: Percentages of pixels passing a ±5%/3mm gamma criterion for previous head and 
neck audits are reported. Agreement was evaluated in the axial and sagittal planes. 
 
Delivery 
DPM TPS 
Axial Coronal Sagittal Axial Coronal Sagittal 
Lung Plan 
#1 99.7 99.0 94.9 97.4 95.5 86.8 
Lung Plan 
#2 88.4 79.1 82.6 96.0 93.3 66.8 
Lung Plan 
#3 92.1 92.6 97.1 64.1 53.6 64.1 
 
Table 5.7: Percentages of pixels passing a ±3%/2mm gamma criterion for previous lung audits 
are reported. Agreement was evaluated in the axial, coronal and sagittal planes. 
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Delivery 
DPM TPS 
Axial Coronal Sagittal Axial Coronal Sagittal 
Lung Plan 
#1 99.9 99.0 99.6 99.9 99.9 99.4 
Lung Plan 
#2 99.0 96.9 99.5 99.9 99.8 93.2 
Lung Plan 
#3 99.1 99.6 99.8 85.7 82.5 82.4 
 
Table 5.8: Percentages of pixels passing a ±5%/3mm gamma criterion for previous lung audits 
are reported. Agreement was evaluated in the axial, coronal and sagittal planes. 
 
     The average agreement in the head and neck phantom audits using a ±3%/2mm gamma 
criterion was 67.3% and 74.7% for DPM recalculated doses and TPS calculated doses, 
respectively. At a less restrictive ±5%/3mm criterion the average agreement was 86.3% and 
93.0% for the DPM recalculated doses and TPS calculated doses, respectively. Among the four 
film comparison (2 axial, 2 sagittal), TPS calculated doses showed better agreement in three 
comparisons at the ±3%/2mm criterion and all four comparisons at the ±5%/3mm criterion. 
     The average agreement in the lung phantom audits using a ±3%/2mm gamma criterion was 
91.7% and 79.7% for DPM recalculated doses and TPS calculated doses, respectively. Using a 
±5%/3mm criterion the average agreement was 99.2% and 93.6% for DPM recalculated doses 
and TPS calculated doses, respectively. Among the nine film comparisons (3 axial, 3 coronal, 3 
sagittal), the DPM recalculate doses showed superior agreement in seven comparisons at the 
±3%/2mm criterion and five comparisons at a ±5%/3mm criterion. 
     Due to the low number of phantom audits meeting the recalculation selection criteria, it is 
difficult to establish significance or meaning behind the discrepancy in performance for DPM 
recalculated doses and TPS calculated doses. The superior agreement in the lung phantom 
audits can likely be explained by the superior accuracy in radiation transport utilizing the Monte 
Carlo technique compared to deterministic algorithms. It is possible that the inferior 
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performance of the multiple source models in the head and neck phantom audits could be due 
to poorer leaf modeling by the calculation tool. The head and neck phantoms require more 
modulation to achieve the planning criteria compared to the lung phantoms. The increased 
modulation could compound the effects of small differences in modeling techniques.  
 
5.4 Conclusion 
     The multiple source models developed for the RPC’s dose calculation quality assurance tool 
have been used to recalculate doses to the RPC’s anthropomorphic phantoms from previous 
credentialing audits. By using archived CT data sets, DICOM RT plan files, and TLD and film 
measurements, the models’ performance could be assessed against outside institution 
measurements and against the performance of commercial treatment planning systems. This 
assessment was done for five previous credentialing audits consisting of two head and neck 
phantom audits and three lung phantom audits. Audits were chosen based on the availability of 
the necessary archived data and superior performance in the credentialing process. 
     Point dose comparisons using the enclosed TLD capsules in the head and neck phantoms 
showed an average calculated to measurement ratio of 1.019 and 1.020 for DPM recalculated 
doses and TPS calculated doses, respectively. Comparisons in the lung phantoms showed an 
average calculated to measurement ratio of 0.986 and 1.023 for DPM recalculated doses and 
TPS calculated doses, respectively. Differences in the head and neck phantom were not 
significant, and while significantly different in the lung phantoms, the performance was not 
significantly better for either calculation method. 
     To assess the ability of the two dose calculation methods’ ability to predict complex dose 
distributions in both homogenous and heterogeneous media, a comparison of film 
measurement to calculated dose was performed for both phantoms using the gamma 
technique. At a ±3%/2mm criterion the average agreement for DPM recalculated dose was 
67.3% and 91.7% for head and neck phantoms and lung phantoms, respectively. The TPS 
calculated dose showed average agreements for the same gamma criterion of 74.7% and 
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79.7% for head and neck phantoms and lung phantoms, respectively. Differences in 
performance suspected to be attributable to superior accuracy in transport in heterogeneous 
media for the Monte Carlo technique and more accurate leaf modeling by the TPS. More 
comparisons between DPM recalculated dose and TPS calculated dose are needed fully 
assess these differences.  
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Chapter 6: Summary 
6.1 Summary for Elekta Models 
     Multiple source models for Elekta 6MV and 10MV beams were developed (Chapter 3) in a 
two-step commissioning process. First energy spectra were optimized by a comparison of 
central axis depth dose data in water for Monte Carlo calculated dose and measured dose. 
Next off-axis effects were accounted for in matching Monte Carlo calculated dose profiles to 
measured dose profiles for a 40 x 40 cm2 field size. The commissioned models were then 
validated against open field measurements consisting of depth dose curves and dose profiles 
at field sizes from 3 x 3 cm 2 to 30 x 30 cm2. Agreement was evaluated using the gamma 
technique and a criterion of ±2% of the maximum dose and ±2mm distance to agreement. All 
depth dose and dose profile comparisons exceeded 90% of data passing the criterion. 
     The multiple source models were then benchmarked against clinically realistic treatment 
deliveries using measurements from anthropomorphic phantoms. Treatments consisted of an 
IMRT head and neck plan, a 3D conformal SBRT lung plan, and an IMRT lung plan. 
Measurements from TLD and film were used to compare the models’ performance to 
measurement. Agreement for dose distributions measured by the film was assessed using the 
gamma technique and a ±3% of the maximum dose and ±2mm distance to agreement criterion. 
All film planes for each treatment delivery averaged over 85% of data passing the established 
criterion. 
 
6.2 Summary for Varian TrueBeam FFF Models 
     Multiple source models for Varian TrueBeam FFF 6MV and FFF 10MV beams were 
developed (Chapter 4) in a two-step commissioning process. First the energy spectra were 
determined from an optimization process based on a comparison of Monte Carlo calculated 
central axis depth dose data to measured central axis depth dose data. Next the off-axis effects 
were accounted for by matching calculated dose profiles measured dose profiles for a 40 x 40 
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cm2 field size. The models were then validated against open field measurements in a water 
tank at field sizes from 3 x 3 cm 2 to 40 x 40 cm2. Agreement between calculation and 
measurement was assessed using the gamma technique and a criterion of ±2% of the 
maximum dose and ±2mm distance to agreement. All depth dose and dose profile comparisons 
exceeded 88% of the data passing the criterion. 
     The developed source models were then benchmarked against clinically realistic treatment 
deliveries using anthropomorphic phantoms. The treatment plans designed to increasingly 
challenge the models and consisted of an IMRT head and neck delivery, a 3D conformal SBRT 
lung delivery, and an IMRT lung delivery. Performance of the model was assessed through a 
comparison of dose calculations to TLD measurement and film measurement. Dose distribution 
agreement was assessed in the film comparison using the gamma technique and a ±3% of the 
maximum dose and ±2mm distance to agreement criterion. All film planes from all deliveries 
averaged over 85% of data passing the criterion. 
 
6.3 Summary for Robustness Study 
     To evaluate the robustness of the multiple source models developed in Chapter 3 and 
Chapter 4 and their feasibility for use in a dose calculation quality assurance audit tool, a 
retrospective analysis of recalculated dose with respect to measurement was performed on 
archived credentialing audits (Chapter 5). Phantom audits that were performed on therapeutic 
x-ray beams fitting the description of the models and with superior performance on the audit 
were chosen for analysis. Selected audits for comparison consisted of both lung phantom 
deliveries and head and neck phantom deliveries. Archived DICOM RT files were used to 
recalculate the phantom dose using the multiple source models and performance was 
evaluated by comparing to archived measurements from the audit.  Performance of the multiple 
source model comparisons was then compared to performance of the treatment planning 
system calculated dose. 
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     Point dose comparisons using the calculated dose to TLD measured dose ratio from the 
head and neck phantoms showed comparable performance for the DPM recalculated dose, 
1.019, with respect to the TPS calculated dose, 1.020. Dose distribution comparisons of 
calculated dose to film measurements evaluated using the gamma technique and a ±3% of the 
maximum dose and ±2mm distance to agreement showed superior performance from the TPS 
calculations, 74.7% of data passing, compared to the DPM recalculated dose, 67.3% of data 
passing. 
     Point dose comparisons using the calculated dose to TLD measured dose ratio from the 
lung phantoms showed statistically significant differences between DPM recalculated dose, 
0.986 and TPS calculated dose, 1.023. Accuracy, however, was not significant. The dose 
distributions were evaluated using film measurement and the gamma technique with a ±3% of 
the maximum dose and ±2mm distance to agreement criterion. The average percent of pixels 
passing was higher in the DPM recalculated dose, 91.7%, compared to the TPS calculated 
dose, 79.7%. 
 
6.4 Evaluation of the Hypothesis 
     The hypothesis to the project was that Monte Carlo, multiple source models of Elekta 6MV, 
Elekta 10MV, Varian TrueBeam FFF 6MV, and Varian TrueBeam FFF 10MV beams could be 
developed based on measurements to an accuracy of ±3% of the maximum dose and ±2mm 
distance to agreement in anthropomorphic phantom measurements.  
     The development and validation of the source models (Specific Aim #1) is documented in 
Chapter 3 (Elekta) and Chapter 4 (Varian TrueBeam FFF). This needed to be done at an 
accuracy of ±2% of the maximum dose and ±2mm distance to agreement compared to open 
field, water tank measurements. 
     They hypothesis was then evaluated in benchmark testing performed against 
anthropomorphic phantoms. The conditions under which the hypothesis was tested are outlined 
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in Specific Aim #2 and Chapter 3 (Elekta) and Chapter 4 (Varian TrueBeam FFF). The 
treatment plans for the phantoms were designed to present increasingly challenging dose 
calculation conditions and consisted of an IMRT head and neck plan, a 3D conformal SBRT 
lung plan, and an IMRT lung plan. Reported average agreement for all four multiple source 
models in each plane of evaluation for all treatment plans exceeded 85%. The results of the 
benchmark testing proved the hypothesis true.  
 
6.5 General Conclusions 
     Development of an independent, dose calculation, quality assurance tool for clinical trial 
audits was completed through the addition of multiple source models of Elekta 6MV and 10MV 
and Varian TrueBeam FFF 6MV and FFF 10MV beams to the already developed Varian 6MV 
and 10MV models. The new models were validated against water tank measurements for open 
fields with excellent agreement. The models then met the benchmarking criteria established to 
show a high degree of accuracy in clinically realistic treatment plans delivered to 
anthropomorphic phantoms. These treatment plans consisted of modulated and un-modulated 
plans delivered to homogeneous and heterogeneous media. As a proof of concept of the tool’s 
utility in this role, a retrospective analysis of past phantom credentialing audits was performed 
with the dose calculation tool. The excellent agreement in the benchmarking studies and 
successful use in a retrospective study suggest that the tool is ready for implementation in the 
RPC’s quality assurance program. 
 
6.6 Future Work 
     The addition of Elekta 6MV and 10MV and Varian TrueBeam FFF 6MV and FFF 10MV 
beams to the previously existing Varian 6MV and 10MV models makes the independent dose 
calculation quality assurance tool developed useful for auditing purposes. Deficiencies in the 
models’ benchmarking and ability to handle some treatment techniques still exist. To date, 
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models have only been benchmarked against step and shoot technique for IMRT deliveries. 
While adaptation to a sliding window technique will not fundamentally change the way the 
model calculates dose, the models should be benchmarked to confirm this. A more significant 
modification of the model will be needed to account for volumetric arc therapy (VMAT) 
deliveries. These have become increasingly popular treatment techniques and due to the way 
in which the model breaks the calculations down by beam and samples particle origin by 
fluence segments, VMAT deliveries cannot not be currently handled by the tool. Inclusion of 
this technique will require a modification to the sampling done in particle generation. 
     With a functioning dose calculation tool it will also be increasingly important that institutions 
submit DICOM RT plan files as a part of phantom audits. This is necessary if the dose 
calculations submitted by institutions are to be checked and will allow for larger scale data 
collection in comparing the performance of specific dose calculation algorithms to the dose 
calculation tool. Chapter 5 suffered from a lack of data points caused largely by a lack of 
archived audits containing DICOM RT plan information needed for the dose calculations.  
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Chapter 7: Appendix 
7.1 Elekta 6 MV: Percent Depth Dose and Dose Profiles 
 
 
Figure 7.1: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 6MV beam at a field size of 3 x 3 cm2. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 99.43% of all data passed the gamma criterion. 
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Figure 7.2: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 6MV beam at a field size of 5 x 5 cm2. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 99.43% of all data passed the gamma criterion. 
 
Figure 7.3: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 6MV beam at a field size of 10 x 10 cm2. Gamma agreement (red circles) for each point 
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 100% of all data passed the gamma criterion. 
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Figure 7.4: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 6MV beam at a field size of 15 x 15 cm2. Gamma agreement (red circles) for each point 
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 100% of all data passed the gamma criterion. 
 
Figure 7.5: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 6MV beam at a field size of 20 x 20 cm2. Gamma agreement (red circles) for each point 
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 99.43% of all data passed the gamma criterion. 
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Figure 7.6: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 6MV beam at a field size of 30 x 30 cm2. Gamma agreement (red circles) for each point 
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 99.43% of all data passed the gamma criterion. 
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Figure 7.7: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 6MV 
beam at a field size of 3 x 3 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
3 x 3 
x 1.6 95.00 
x 5 100.00 
x 10 100.00 
x 20 100.00 
y 1.6 97.14 
y 5 100.00 
y 10 100.00 
y 20 100.00 
 
Table 7.1: Dose profile agreement between the Elekta 6MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 3 x 3 
cm2 field size. 
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Figure 7.8: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 6MV 
beam at a field size of 5 x 5 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
5 x 5 
x 1.6 98.04 
x 5 100.00 
x 10 100.00 
x 20 100.00 
y 1.6 97.92 
y 5 100.00 
y 10 100.00 
y 20 100.00 
 
Table 7.2: Dose profile agreement between the Elekta 6MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 5 x 5 
cm2 field size. 
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Figure 7.9: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 6MV 
beam at a field size of 10 x 10 cm2.  
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
10 x 10 
x 1.6 96.34 
x 5 100.00 
x 10 100.00 
x 20 100.00 
y 1.6 100.00 
y 5 100.00 
y 10 100.00 
y 20 100.00 
 
Table 7.3: Dose profile agreement between the Elekta 6MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 10 x 
10 cm2 field size. 
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Figure 7.10: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
6MV beam at a field size of 15 x 15 cm2.  
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
15 x 15 
x 1.6 94.78 
x 5 100.00 
x 10 100.00 
x 20 100.00 
y 1.6 100.00 
y 5 100.00 
y 10 100.00 
y 20 100.00 
 
Table 7.4: Dose profile agreement between the Elekta 6MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 15 x 
15 cm2 field size. 
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Figure 7.11: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
6MV beam at a field size of 20 x 20 cm2.  
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
20 x 20 
x 1.6 98.68 
x 5 99.51 
x 10 100.00 
x 20 100.00 
y 1.6 97.98 
y 5 100.00 
y 10 99.51 
y 20 100.00 
 
Table 7.5: Dose profile agreement between the Elekta 6MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 20 x 
20 cm2 field size. 
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Figure 7.12: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
6MV beam at a field size of 30 x 30 cm2.  
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
30 x 30 
x 1.6 98.50 
x 5 99.51 
x 10 100.00 
x 20 100.00 
y 1.6 97.98 
y 5 100.00 
y 10 99.51 
y 20 100.00 
 
Table 7.6: Dose profile agreement between the Elekta 6MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 30 x 
30 cm2 field size. 
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7.2 Elekta 6 MV: Gamma Maps 
7.2.1 Elekta 6 MV: Delivery of IMRT Head and Neck Plan 
 
Figure 7.13: IMRT head and neck delivery comparison for the axial plane of delivery #2 for the 
Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 87.6% of 
pixels passed.  
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Figure 7.14: IMRT head and neck delivery comparison for the sagittal plane of delivery #2 for 
the Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
86.7% of pixels passed.  
 
Figure 7.15: IMRT head and neck delivery comparison for the axial plane of delivery #3 for the 
Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 82.5% of 
pixels passed.  
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Figure 7.16: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for 
the Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
86.1% of pixels passed.  
 
  
169 
 
7.2.2 Elekta 6 MV: Delivery of SBRT Lung Plan 
 
Figure 7.17: Lung SBRT delivery comparison for the axial plane of delivery #2 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 86.2% of pixels 
passed.  
  
170 
 
 
Figure 7.18: Lung SBRT delivery comparison for the sagittal plane of delivery #2 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.3% of pixels 
passed.  
 
Figure 7.19: Lung SBRT delivery comparison for the coronal plane of delivery #2 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.9% of pixels 
passed. 
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Figure 7.20: Lung SBRT delivery comparison for the axial plane of delivery #3 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.0% of pixels 
passed.  
 
Figure 7.21: Lung SBRT delivery comparison for the sagittal plane of delivery #3 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 84.2% of pixels 
passed.  
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Figure 7.22: Lung SBRT delivery comparison for the coronal plane of delivery #3 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 88.1% of pixels 
passed. 
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7.2.3 Elekta 6 MV: Delivery of IMRT Lung Plan 
 
Figure 7.23: Lung IMRT delivery comparison for the axial plane of delivery #1 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 82.6% of pixels 
passed.  
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Figure 7.24: Lung IMRT delivery comparison for the sagittal plane of delivery #1 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 92.5% of pixels 
passed.  
 
Figure 7.25: Lung IMRT delivery comparison for the coronal plane of delivery #1 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.8% of pixels 
passed. 
175 
 
 
Figure 7.26: Lung IMRT delivery comparison for the axial plane of delivery #2 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.4% of pixels 
passed.  
 
Figure 7.27: Lung IMRT delivery comparison for the sagittal plane of delivery #2 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 83.5% of pixels 
passed.  
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Figure 7.28: Lung IMRT delivery comparison for the coronal plane of delivery #2 for the Elekta 
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.8% of pixels 
passed. 
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7.3 Elekta 10 MV: Percent Depth Dose and Dose Profiles 
 
 
Figure 7.29: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 10MV beam at a field size of 3 x 3 cm2. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 99.43% of all data passed the gamma criterion. 
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Figure 7.30: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 10MV beam at a field size of 5 x 5 cm2. Gamma agreement (red circles) for each point is 
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 99.43% of all data passed the gamma criterion. 
 
Figure 7.31: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 10MV beam at a field size of 10 x 10 cm2. Gamma agreement (red circles) for each point 
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 99.43% of all data passed the gamma criterion. 
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Figure 7.32: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 10MV beam at a field size of 15 x 15 cm2. Gamma agreement (red circles) for each point 
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 100% of all data passed the gamma criterion. 
 
Figure 7.33: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 10MV beam at a field size of 20 x 20 cm2. Gamma agreement (red circles) for each point 
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 100% of all data passed the gamma criterion. 
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Figure 7.34: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an 
Elekta 10MV beam at a field size of 30 x 30 cm2. Gamma agreement (red circles) for each point 
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 100% of all data passed the gamma criterion. 
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Figure 7.35: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 3 x 3 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
3 x 3 
x 1.6 95.65 
x 5 100.00 
x 10 100.00 
x 20 100.00 
x 25 100.00 
y 1.6 100.00 
y 5 100.00 
y 10 100.00 
y 20 100.00 
y 25 100.00 
 
Table 7.7: Dose profile agreement between the Elekta 10MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 3 x 3 
cm2 field size. 
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Figure 7.36: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 5 x 5 cm2.  
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
5 x 5 
x 1.6 100.00 
x 5 100.00 
x 10 100.00 
x 20 100.00 
x 25 100.00 
y 1.6 100.00 
y 5 100.00 
y 10 100.00 
y 20 100.00 
y 25 100.00 
 
Table 7.8: Dose profile agreement between the Elekta 10MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 5 x 5 
cm2 field size. 
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Figure 7.37: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 10 x 10 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
10 x 10 
x 1.6 100.00 
x 5 100.00 
x 10 100.00 
x 20 100.00 
x 25 100.00 
y 1.6 100.00 
y 5 100.00 
y 10 100.00 
y 20 100.00 
y 25 100.00 
 
Table 7.9: Dose profile agreement between the Elekta 10MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 10 x 
10 cm2 field size. 
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Figure 7.38: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 15 x 15 cm2. 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
15 x 15 
x 1.6 94.95 
x 5 100.00 
x 10 100.00 
x 20 100.00 
x 25 100.00 
y 1.6 100.00 
y 5 100.00 
y 10 100.00 
y 20 100.00 
y 25 100.00 
 
Table 7.10: Dose profile agreement between the Elekta 10MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 15 x 
15 cm2 field size. 
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Figure 7.39: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 20 x 20 cm2.  
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
20 x 20 
x 1.6 90.98 
x 5 98.51 
x 10 100.00 
x 20 100.00 
x 25 100.00 
y 1.6 99.19 
y 5 100.00 
y 10 100.00 
y 20 100.00 
y 25 100.00 
 
Table 7.11: Dose profile agreement between the Elekta 10MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 20 x 
20 cm2 field size. 
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Figure 7.40: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 
10MV beam at a field size of 30 x 30 cm2.  
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
30 x 30 
x 1.6 98.97 
x 5 100.00 
x 10 100.00 
x 20 100.00 
x 25 100.00 
y 1.6 99.45 
y 5 100.00 
y 10 100.00 
y 20 100.00 
y 25 100.00 
 
Table 7.12: Dose profile agreement between the Elekta 10MV multiple source model and 
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 30 x 
30 cm2 field size. 
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7.4 Elekta 10 MV: Gamma Maps 
7.4.1 Elekta 10 MV: Delivery of IMRT Head and Neck Plan 
 
Figure 7.41: IMRT head and neck delivery comparison for the axial plane of delivery #2 for the 
Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 91.6% 
of pixels passed.  
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Figure 7.42: IMRT head and neck delivery comparison for the sagittal plane of delivery #2 for 
the Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
86.4% of pixels passed.  
 
Figure 7.43: IMRT head and neck delivery comparison for the axial plane of delivery #3 for the 
Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 95.9% 
of pixels passed.  
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Figure 7.44: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for 
the Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
87.3% of pixels passed.  
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7.4.2 Elekta 10 MV: Delivery of SBRT Lung Plan 
 
Figure 7.45: Lung SBRT delivery comparison for the axial plane of delivery #2 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 86.2% of 
pixels passed.  
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Figure 7.46: Lung SBRT delivery comparison for the sagittal plane of delivery #2 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 90.8% of 
pixels passed.  
 
Figure 7.47: Lung SBRT delivery comparison for the coronal plane of delivery #2 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.3% of 
pixels passed.  
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Figure 7.48: Lung SBRT delivery comparison for the axial plane of delivery #3 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 88.1% of 
pixels passed.  
 
Figure 7.49: Lung SBRT delivery comparison for the sagittal plane of delivery #3 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.2% of 
pixels passed.  
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Figure 7.50: Lung SBRT delivery comparison for the coronal plane of delivery #3 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 90.5% of 
pixels passed.   
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7.4.3 Elekta 10 MV: Delivery of IMRT Lung Plan 
 
Figure 7.51: Lung IMRT delivery comparison for the axial plane of delivery #2 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.8% of 
pixels passed.  
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Figure 7.52: Lung IMRT delivery comparison for the sagittal plane of delivery #2 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 87.3% of 
pixels passed.  
 
Figure 7.53: Lung IMRT delivery comparison for the coronal plane of delivery #2 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.3% of 
pixels passed.  
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Figure 7.54: Lung IMRT delivery comparison for the axial plane of delivery #3 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 92.5% of 
pixels passed.  
 
Figure 7.55: Lung IMRT delivery comparison for the sagittal plane of delivery #3 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 94.0% of 
pixels passed.  
197 
 
 
Figure 7.56: Lung IMRT delivery comparison for the coronal plane of delivery #3 for the Elekta 
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 88.5% of 
pixels passed.  
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7.5 Varian TrueBeam 6 MV: Percent Depth Dose and Dose Profiles 
 
Figure 7.57: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 6MV beam at a field size of 3 x 3 cm2. Gamma agreement (red circles) for each 
point is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 100.0% of all data passed the gamma criterion. 
 
Figure 7.58: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 6MV beam at a field size of 4 x 4 cm2. Gamma agreement (red circles) for each 
point is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 100.0% of all data passed the gamma criterion. 
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Figure 7.59: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 6MV beam at a field size of 6 x 6 cm2. Gamma agreement (red circles) for each 
point is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 99.33% of all data passed the gamma criterion. 
 
Figure 7.60: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 6MV beam at a field size of 8 x 8 cm2. Gamma agreement (red circles) for each 
point is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm 
criterion. At this field size 100.0% of all data passed the gamma criterion. 
200 
 
 
Figure 7.61: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 6MV beam at a field size of 10 x 10 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion. 
 
Figure 7.62: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 6MV beam at a field size of 20 x 20 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion. 
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Figure 7.63: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 6MV beam at a field size of 30 x 30 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion. 
 
Figure 7.64: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 6MV beam at a field size of 40 x 40 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion. 
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Figure 7.65: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
6MV beam at a field size of 3 x 3 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
3 x 3 
x 1.5 98.45 
x 5 98.45 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.13: Dose profile agreement between the TrueBeam FFF 6MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 3 
x 3 cm2 field size. 
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Figure 7.66: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
6MV beam at a field size of 4 x 4 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
4 x 4 
x 1.5 96.45 
x 5 98.58 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.14: Dose profile agreement between the TrueBeam FFF 6MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 4 
x 4 cm2 field size. 
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Figure 7.67: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
6MV beam at a field size of 6 x 6 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
6 x 6 
x 1.5 98.76 
x 5 99.34 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.15: Dose profile agreement between the TrueBeam FFF 6MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 6 
x 6 cm2 field size. 
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Figure 7.68: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
6MV beam at a field size of 8 x 8 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
8 x 8 
x 1.5 96.13 
x 5 100.00 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.16: Dose profile agreement between the TrueBeam FFF 6MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 8 
x 8 cm2 field size. 
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Figure 7.69: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
6MV beam at a field size of 10 x 10 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
10 x 10 
x 1.5 93.97 
x 5 99.50 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.17: Dose profile agreement between the TrueBeam FFF 6MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 
10 x 10 cm2 field size. 
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Figure 7.70: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
6MV beam at a field size of 20 x 20 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
20 x 20 
x 1.5 88.04 
x 5 89.04 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.18: Dose profile agreement between the TrueBeam FFF 6MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 
20 x 20 cm2 field size. 
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Figure 7.71: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
6MV beam at a field size of 30 x 30 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
30 x 30 
x 1.5 88.04 
x 5 89.04 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.19: Dose profile agreement between the TrueBeam FFF 6MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 
30 x 30 cm2 field size. 
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Figure 7.72: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
6MV beam at a field size of 40 x 40 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
40 x 40 
x 1.5 89.91 
x 5 90.50 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.20: Dose profile agreement between the TrueBeam FFF 6MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 
40 x 40 cm2 field size. 
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7.6 Varian TrueBeam 6 MV: Gamma Maps 
7.6.1 Varian TrueBeam 6 MV: Delivery of IMRT Head and Neck Plan 
 
Figure 7.73: IMRT head and neck delivery comparison for the axial plane of delivery #2 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
89.4% of pixels passed.  
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Figure 7.74: IMRT head and neck delivery comparison for the sagittal plane of delivery #2 for 
the TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 86.6% of pixels passed.  
 
Figure 7.75: IMRT head and neck delivery comparison for the axial plane of delivery #3 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
80.3% of pixels passed.  
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Figure 7.76: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for 
the TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 95.9% of pixels passed.  
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7.6.2 Varian TrueBeam 6 MV: Delivery of SBRT Lung Plan 
 
Figure 7.77: Lung SBRT delivery comparison for the axial plane of delivery #2 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
84.5% of pixels passed.  
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Figure 7.78: Lung SBRT delivery comparison for the sagittal plane of delivery #2 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
90.3% of pixels passed.  
 
Figure 7.79: Lung SBRT delivery comparison for the coronal plane of delivery #2 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
98.4% of pixels passed. 
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Figure 7.80: Lung SBRT delivery comparison for the axial plane of delivery #3 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
87.5% of pixels passed.  
 
Figure 7.81: Lung SBRT delivery comparison for the sagittal plane of delivery #3 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
95.2% of pixels passed.  
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Figure 7.82: Lung SBRT delivery comparison for the coronal plane of delivery #3 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
85.5% of pixels passed. 
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7.6.3 Varian TrueBeam 6 MV: Delivery of IMRT Lung Plan 
 
Figure 7.83: Lung IMRT delivery comparison for the axial plane of delivery #2 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
91.4% of pixels passed.  
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Figure 7.84: Lung IMRT delivery comparison for the sagittal plane of delivery #2 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
87.4% of pixels passed.  
 
Figure 7.85: Lung IMRT delivery comparison for the coronal plane of delivery #2 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
88.4% of pixels passed. 
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Figure 7.86: Lung IMRT delivery comparison for the axial plane of delivery #3 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
93.5% of pixels passed.  
 
Figure 7.87: Lung IMRT delivery comparison for the sagittal plane of delivery #3 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
94.3% of pixels passed.  
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Figure 7.88: Lung IMRT delivery comparison for the coronal plane of delivery #3 for the 
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 
92.4% of pixels passed.  
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7.7 Varian TrueBeam 10 MV: Percent Depth Dose and Dose Profiles 
 
Figure 7.89: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 10MV beam at a field size of 3 x 3 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 99.3% of all data passed the gamma criterion. 
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Figure 7.90: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 10MV beam at a field size of 4 x 4 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 99.3% of all data passed the gamma criterion. 
 
Figure 7.91: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 10MV beam at a field size of 6 x 6 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 99.3% of all data passed the gamma criterion. 
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Figure 7.92: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 10MV beam at a field size of 8 x 8 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion. 
 
Figure 7.93: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 10MV beam at a field size of 10 x 10 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion. 
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Figure 7.94: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 10MV beam at a field size of 20 x 20 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion. 
 
Figure 7.95: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 10MV beam at a field size of 30 x 30 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 97.4% of all data passed the gamma criterion. 
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Figure 7.96: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a 
TrueBeam FFF 10MV beam at a field size of 40 x 40 cm2. Gamma agreement (red circles) for 
each point is also displayed along with any points (red star) at which a failure to meet the 
±2%/2mm criterion. At this field size 96.7% of all data passed the gamma criterion. 
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Figure 7.97: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 3 x 3 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
3 x 3 
x 2.4 94.57 
x 5 100.00 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.21: Dose profile agreement between the TrueBeam FFF 10MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 3 
x 3 cm2 field size. 
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Figure 7.98: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 4 x 4 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
4 x 4 
x 2.4 100.00 
x 5 98.56 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.22: Dose profile agreement between the TrueBeam FFF 10MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 4 
x 4 cm2 field size. 
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Figure 7.99: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 6 x 6 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
6 x 6 
x 2.4 98.74 
x 5 99.37 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.23: Dose profile agreement between the TrueBeam FFF 10MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 6 
x 6 cm2 field size. 
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Figure 7.100: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 8 x 8 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
8 x 8 
x 2.4 96.10 
x 5 98.88 
x 10 96.65 
x 20 100.00 
x 30 100.00 
 
Table 7.24: Dose profile agreement between the TrueBeam FFF 10MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 8 
x 8 cm2 field size. 
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Figure 7.101: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 10 x 10 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
10 x 10 
x 2.4 93.47 
x 5 96.98 
x 10 90.45 
x 20 100.00 
x 30 100.00 
 
Table 7.25: Dose profile agreement between the TrueBeam FFF 10MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 
10 x 10 cm2 field size. 
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Figure 7.102: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 20 x 20 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
20 x 20 
x 2.4 99.67 
x 5 93.07 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.26: Dose profile agreement between the TrueBeam FFF 10MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 
20 x 20 cm2 field size. 
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Figure 7.103: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 30 x 30 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
30 x 30 
x 2.4 90.17 
x 5 90.42 
x 10 100.00 
x 20 100.00 
x 30 100.00 
 
Table 7.27: Dose profile agreement between the TrueBeam FFF 10MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 
30 x 30 cm2 field size. 
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Figure 7.104: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam 
FFF 10MV beam at a field size of 40 x 40 cm2.  
 
Field Size (cm2) Direction Depth (cm) % Passing (2%/2mm) 
40 x 40 
x 2.4 88.61 
x 5 90.18 
x 10 100.00 
x 20 100.00 
x 30 99.61 
 
Table 7.28: Dose profile agreement between the TrueBeam FFF 10MV multiple source model 
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 
40 x 40 cm2 field size. 
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7.8 Varian TrueBeam 10 MV: Gamma Maps 
7.8.1 Varian TrueBeam 10 MV: Delivery of IMRT Head and Neck Plan 
 
Figure 7.105: IMRT head and neck delivery comparison for the axial plane of delivery #2 for 
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 93.1% of pixels passed.  
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Figure 7.106: IMRT head and neck delivery comparison for the sagittal plane of delivery #2 for 
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 85.9% of pixels passed.  
 
Figure 7.107: IMRT head and neck delivery comparison for the axial plane of delivery #3 for 
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 75.5% of pixels passed.  
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Figure 7.108: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for 
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 90.1% of pixels passed.  
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7.8.2 Varian TrueBeam 10 MV: Delivery of SBRT Lung Plan 
 
Figure 7.109: Lung SBRT delivery comparison for the axial plane of delivery #2 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 87.4% of pixels passed.  
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Figure 7.110: Lung SBRT delivery comparison for the sagittal plane of delivery #2 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 88.1% of pixels passed.  
 
Figure 7.111: Lung SBRT delivery comparison for the coronal plane of delivery #2 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 92.7% of pixels passed. 
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Figure 7.112: Lung SBRT delivery comparison for the axial plane of delivery #3 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 95.8% of pixels passed.  
 
Figure 7.113: Lung SBRT delivery comparison for the sagittal plane of delivery #3 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 91.4% of pixels passed.  
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Figure 7.114: Lung SBRT delivery comparison for the coronal plane of delivery #3 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 98.1% of pixels passed. 
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7.8.3 Varian TrueBeam 10 MV: Delivery of IMRT Lung Plan 
 
Figure 7.115: Lung IMRT delivery comparison for the axial plane of delivery #1 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 95.6% of pixels passed.  
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Figure 7.116: Lung IMRT delivery comparison for the sagittal plane of delivery #1 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 84.2% of pixels passed.  
 
Figure 7.117: Lung IMRT delivery comparison for the coronal plane of delivery #1 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 92.1% of pixels passed. 
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Figure 7.118: Lung IMRT delivery comparison for the axial plane of delivery #2 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 97.4% of pixels passed.  
 
Figure 7.119: Lung IMRT delivery comparison for the sagittal plane of delivery #2 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 93.6% of pixels passed.  
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Figure 7.120: Lung IMRT delivery comparison for the coronal plane of delivery #2 for the 
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 96.4% of pixels passed.   
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7.9 Outside Institution Robustness Study: Gamma Maps 
7.9.1 Head and Neck Phantom Audits 
 
Figure 7.121: IMRT head and neck delivery comparison for the axial plane of Head and Neck 
Plan #1 with respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm 
gamma criterion and 59.1% of pixels passed. 
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Figure 7.122: IMRT head and neck delivery comparison for the sagittal plane of Head and 
Neck Plan #1 with respect to DPM recalculated dose. Agreement was evaluated using a 
±3%/2mm gamma criterion and 69.4% of pixels passed. 
 
Figure 7.123: IMRT head and neck delivery comparison for the axial plane of Head and Neck 
Plan #1 with respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm 
gamma criterion and 82.1% of pixels passed. 
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Figure 7.124: IMRT head and neck delivery comparison for the sagittal plane of Head and 
Neck Plan #1 with respect to DPM recalculated dose. Agreement was evaluated using a 
±5%/3mm gamma criterion and 88.2% of pixels passed. 
 
Figure 7.125: IMRT head and neck delivery comparison for the axial plane of Head and Neck 
Plan #1 with respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm 
gamma criterion and 67.6% of pixels passed. 
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Figure 7.126: IMRT head and neck delivery comparison for the sagittal plane of Head and 
Neck Plan #1 with respect to TPS calculated dose. Agreement was evaluated using a 
±3%/2mm gamma criterion and 75.3% of pixels passed. 
 
Figure 7.127: IMRT head and neck delivery comparison for the axial plane of Head and Neck 
Plan #1 with respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm 
gamma criterion and 88.6% of pixels passed. 
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Figure 7.128: IMRT head and neck delivery comparison for the sagittal plane of Head and 
Neck Plan #1 with respect to TPS calculated dose. Agreement was evaluated using a 
±5%/3mm gamma criterion and 98.9% of pixels passed. 
 
Figure 7.129: IMRT head and neck delivery comparison for the axial plane of Head and Neck 
Plan #2 with respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm 
gamma criterion and 88.4% of pixels passed. 
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Figure 7.130: IMRT head and neck delivery comparison for the sagittal plane of Head and 
Neck Plan #2 with respect to DPM recalculated dose. Agreement was evaluated using a 
±3%/2mm gamma criterion and 52.5% of pixels passed. 
 
Figure 7.131: IMRT head and neck delivery comparison for the axial plane of Head and Neck 
Plan #2 with respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm 
gamma criterion and 98.3% of pixels passed. 
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Figure 7.132: IMRT head and neck delivery comparison for the sagittal plane of Head and 
Neck Plan #2 with respect to DPM recalculated dose. Agreement was evaluated using a 
±5%/3mm gamma criterion and 76.8% of pixels passed. 
 
Figure 7.133: IMRT head and neck delivery comparison for the axial plane of Head and Neck 
Plan #2 with respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm 
gamma criterion and 85.9% of pixels passed. 
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Figure 7.134: IMRT head and neck delivery comparison for the axial plane of Head and Neck 
Plan #2 with respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm 
gamma criterion and 69.8% of pixels passed. 
 
Figure 7.135: IMRT head and neck delivery comparison for the sagittal plane of Head and 
Neck Plan #2 with respect to TPS calculated dose. Agreement was evaluated using a 
±5%/3mm gamma criterion and 98.4% of pixels passed. 
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Figure 7.136: IMRT head and neck delivery comparison for the sagittal plane of Head and 
Neck Plan #2 with respect to TPS calculated dose. Agreement was evaluated using a 
±5%/3mm gamma criterion and 86.3% of pixels passed. 
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7.9.2 Lung Phantom Audits 
 
 
Figure 7.137: Lung phantom delivery comparison for the axial plane of Lung Plan #1 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 99.7% of pixels passed. 
 
 
 
255 
 
 
Figure 7.138: Lung phantom delivery comparison for the coronal plane of Lung Plan #1 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 99.0% of pixels passed. 
 
Figure 7.139: Lung phantom delivery comparison for the sagittal plane of Lung Plan #1 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 94.9% of pixels passed. 
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Figure 7.140: Lung phantom delivery comparison for the axial plane of Lung Plan #1 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 99.9% of pixels passed. 
 
Figure 7.141: Lung phantom delivery comparison for the coronal plane of Lung Plan #1 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 99.0% of pixels passed. 
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Figure 7.142: Lung phantom delivery comparison for the sagittal plane of Lung Plan #1 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 99.6% of pixels passed. 
 
Figure 7.143: Lung phantom delivery comparison for the axial plane of Lung Plan #1 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 97.4% of pixels passed. 
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Figure 7.144: Lung phantom delivery comparison for the coronal plane of Lung Plan #1 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 95.5% of pixels passed. 
 
Figure 7.145: Lung phantom delivery comparison for the sagittal plane of Lung Plan #1 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 86.8% of pixels passed. 
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Figure 7.146: Lung phantom delivery comparison for the axial plane of Lung Plan #1 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 99.9% of pixels passed. 
 
Figure 7.147: Lung phantom delivery comparison for the coronal plane of Lung Plan #1 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 99.9% of pixels passed. 
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Figure 7.148: Lung phantom delivery comparison for the sagittal plane of Lung Plan #1 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 99.4% of pixels passed. 
 
Figure 7.149: Lung phantom delivery comparison for the axial plane of Lung Plan #2 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 88.4% of pixels passed. 
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Figure 7.150: Lung phantom delivery comparison for the coronal plane of Lung Plan #2 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 79.1% of pixels passed. 
 
Figure 7.151: Lung phantom delivery comparison for the sagittal plane of Lung Plan #2 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 82.6% of pixels passed. 
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Figure 7.152: Lung phantom delivery comparison for the axial plane of Lung Plan #2 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 99.0% of pixels passed. 
 
Figure 7.153: Lung phantom delivery comparison for the coronal plane of Lung Plan #2 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 96.9% of pixels passed. 
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Figure 7.154: Lung phantom delivery comparison for the sagittal plane of Lung Plan #2 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 99.5% of pixels passed. 
 
Figure 7.155: Lung phantom delivery comparison for the axial plane of Lung Plan #2 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 96.0% of pixels passed. 
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Figure 7.156: Lung phantom delivery comparison for the coronal plane of Lung Plan #2 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 93.3% of pixels passed. 
 
Figure 7.157: Lung phantom delivery comparison for the sagittal plane of Lung Plan #2 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 66.8% of pixels passed. 
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Figure 7.158: Lung phantom delivery comparison for the axial plane of Lung Plan #2 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 99.9% of pixels passed. 
 
Figure 7.159: Lung phantom delivery comparison for the coronal plane of Lung Plan #2 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 99.8% of pixels passed. 
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Figure 7.160: Lung phantom delivery comparison for the sagittal plane of Lung Plan #2 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 93.2% of pixels passed. 
 
Figure 7.161: Lung phantom delivery comparison for the axial plane of Lung Plan #3 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 92.1% of pixels passed. 
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Figure 7.162: Lung phantom delivery comparison for the coronal plane of Lung Plan #3 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 92.6% of pixels passed. 
 
Figure 7.163: Lung phantom delivery comparison for the sagittal plane of Lung Plan #3 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma 
criterion and 97.1% of pixels passed. 
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Figure 7.164: Lung phantom delivery comparison for the axial plane of Lung Plan #3 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 99.1% of pixels passed. 
 
Figure 7.165: Lung phantom delivery comparison for the coronal plane of Lung Plan #3 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 99.6% of pixels passed. 
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Figure 7.166: Lung phantom delivery comparison for the sagittal plane of Lung Plan #3 with 
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma 
criterion and 99.8% of pixels passed. 
 
Figure 7.167: Lung phantom delivery comparison for the axial plane of Lung Plan #3 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 64.1% of pixels passed. 
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Figure 7.168: Lung phantom delivery comparison for the coronal plane of Lung Plan #3 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 53.6% of pixels passed. 
 
Figure 7.169: Lung phantom delivery comparison for the sagittal plane of Lung Plan #3 with 
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion 
and 64.1% of pixels passed. 
271 
 
 
Figure 7.170: Lung phantom delivery comparison for the axial plane of Lung Plan #3 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 85.7% of pixels passed. 
 
Figure 7.171: Lung phantom delivery comparison for the coronal plane of Lung Plan #3 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 82.5% of pixels passed. 
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Figure 7.172: Lung phantom delivery comparison for the sagittal plane of Lung Plan #3 with 
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion 
and 82.4% of pixels passed. 
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